Patent Grant
12161865
The invention relates in some aspects to systems and methods for treating overactive bladder and related conditions.
Overactive bladder (OAB) is a common urinary syndrome affecting men and women with an estimated prevalence of 16% of the population. The total annual cost burden of OAB is projected to be up to US$3.9 billion across six countries (Canada, Germany, Italy, Spain, Sweden, and the UK). Symptoms of overactive bladder include the uncontrollable desire to urinate immediately, known as urgency, which may or may not be followed by the involuntary loss of urine (incontinence), increased frequency of urination during the day, and/or increased frequency of waking up from sleep due to a sense of urgency, also known as nocturia. Nocturia is a medical condition that results in the need to wake up two, three, or more times during the night to urinate. Lower urinary tract (LUT) dysfunction may be secondary to a variety of non-neurologic or neurologic causes, including stroke, spinal cord injury, multiple sclerosis or neurodegenerative conditions such as Parkinson's disease. Standard medical treatment options for overactive bladder include behavioral strategies such as restricting fluid intake, timed voiding, or pelvic muscle exercises, or pharmacologic therapies such as antimuscarinic medications or botulinum toxin injections into the bladder. However, oral medications can be incompletely effective and carry a high risk of adverse side effects leading to intolerance and frequent discontinuation. Efficacious therapies with reduced side effects are needed.
In some embodiments, disclosed herein is a method of treating urinary symptoms in a patient with dual transcutaneous stimulation of a saphenous nerve and a tibial nerve. The method can include, in some embodiments, any number of the following: positioning a first peripheral nerve effector on the patient's skin to stimulate the saphenous nerve of the patient; positioning a second peripheral nerve effector on the patient's skin to stimulate the tibial nerve of the patient; delivering a first electrical nerve stimulation signal transcutaneously to the saphenous nerve through the first peripheral nerve effector; delivering a second electrical nerve stimulation signal transcutaneously to the tibial nerve through the second peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. In some embodiments, the method does not utilize any implantable components, and only involves transcutaneous stimulation. The first peripheral nerve effector and the second peripheral nerve effector can be both positioned proximate the knee of the patient. The first electrical stimulation signal can be different from the second electrical stimulation signal. The first electrical stimulation signal can have a first frequency different from a second frequency of the second electrical stimulation signal. The first electrical stimulation signal can have an amplitude different from the second electrical stimulation signal. The first or second frequency can be, for example, from about 10 Hz to about 20 Hz. The first or second frequency can be, for example, from about 5 Hz to about 30 Hz. Receiving an input relating to autonomic nervous system activity of the patient can include any number of the following: receiving data from a sensor that measures autonomic nervous system activity of the patient; receiving data from a sensor that measures heart rate variability of the patient; receiving heart rate variability data from an optical sensor measuring blood flow characteristics and disposed proximate a vessel proximate a knee of the patient; receiving data from a sensor that measures galvanic skin response of the patient; receiving data relating to urinary symptoms of the patient; and/or receiving data relating to nocturia episodes of the patient.
Also disclosed herein is a wearable device for dual transcutaneous stimulation of the saphenous nerve and tibial nerve and for treating urinary symptoms in a patient. The device can include, in some embodiments, any number of the following features: a controller; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate the saphenous nerve; a second peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate the tibial nerve; and at least one biomedical sensor or data input source configured to provide feedback information. The controller can include a processor and a memory for receiving the feedback information from the sensor that, when executed by the processor, cause the device to adjust one or more parameters of a first electrical stimulus and a second electrical stimulus based at least in part on the feedback information; and/or deliver the first electrical stimulus to the saphenous nerve through the first peripheral nerve effector and deliver the second electrical stimulus to the tibial nerve through the second peripheral nerve effector to reduce urinary symptoms by modifying a brain or spinal cord autonomic feedback loop relating to bladder function and balancing sympathetic nerve and parasympathetic nerve activity. In some embodiments, the device is not configured for implantation within the patient. The feedback information can include real-time feedback information. The first electrical stimulus can have a frequency of, for example, between about 10 Hz and about 20 Hz. The second electrical stimulus can have a frequency of, for example, between about 5 Hz and about 30 Hz. The feedback information can include autonomic nervous system activity of the patient. The feedback information can include heart rate variability. The feedback information can also include information relating to nocturia events of the patient. The feedback information can also include information relating to patient sleep state.
In some embodiments, disclosed herein is a method of treating urinary symptoms in a patient. The method can include any number of the following: positioning a first electrode at a first location on a skin surface relative to a first afferent peripheral nerve; positioning a second electrode at a second location on the skin surface relative to a second afferent peripheral nerve; positioning a third electrode at a third location on the skin surface spaced apart from the first electrode and the second electrode; delivering a first stimulus to the first peripheral nerve through the first electrode; and delivering a second stimulus to the second peripheral nerve through the second electrode. In some embodiments, the third electrode is a single common return electrode (which can be referred to as a counter electrode or ground electrode) to the first electrode and the second electrode. In some embodiments, the first electrode, second electrode, and third electrode are positioned such that electric fields between the first electrode and the third electrode pass through the first afferent peripheral nerve to preferentially stimulate the first afferent peripheral nerve, and electric fields between the second electrode and the third electrode pass through the second afferent peripheral nerve to preferentially stimulate the second afferent peripheral nerve. The first stimulus and the second stimulus can modify at least one brain or spinal cord autonomic feedback loop relating to bladder function. In some embodiments, the first afferent peripheral nerve comprises the tibial nerve. In some embodiments, the second afferent peripheral nerve comprises the saphenous nerve. The symptoms can include, for example, overactive bladder, nocturia, urinary urgency, urinary incontinence, and/or urinary frequency. In some embodiments, the first electrode, second electrode, and third electrode are all connected on a wearable device and positioned on the calf proximate to, and distal to the patient's knee, ankle, and/or foot.
In some embodiments, disclosed herein is a method of treating urinary symptoms in a patient. The method can include any number of the following: positioning a first pair of electrodes comprising an anode and a cathode at a first location on a skin surface relative to a first peripheral nerve; positioning a second pair of electrodes comprising an anode and a cathode at a second location on the skin surface relative to a second peripheral nerve; delivering a first stimulus to the first peripheral nerve through the first pair of electrodes; and delivering a second stimulus to the second peripheral nerve through the second pair of electrodes. In some embodiments, the first pair of electrodes and second pair of electrodes are positioned such that electric fields between the first pair of electrodes pass through the first peripheral nerve, and electric fields between the second pair of electrodes pass through the second peripheral nerve. The first stimulus and the second stimulus can modify at least one brain or spinal cord autonomic feedback loop relating to bladder function.
Also disclosed herein is a system of treating urinary symptoms in a patient, that can include in some embodiments any number of the following: a wearable housing configured to be positioned on a patient's calf proximate the knee or ankle of the patient; a first electrode configured to be positioned at a first location on a skin surface relative to a first afferent peripheral nerve; a second electrode configured to be positioned at a second location on the skin surface relative to a second afferent peripheral nerve; a third electrode configured to be positioned at a third location on the skin surface spaced apart from the first electrode and the second electrode; a controller configured to deliver a first stimulus to the first peripheral nerve through the first electrode; and a second stimulus to the second peripheral nerve through the second electrode to modify at least one brain or spinal cord autonomic feedback loop relating to bladder function. The third electrode can be a single common return electrode to the first electrode and the second electrode. The first electrode, second electrode, and third electrode can be configured to be positioned such that electric fields between the first electrode and the third electrode pass through the first afferent peripheral nerve, and electric fields between the second electrode and the third electrode pass through the second afferent peripheral nerve. The wearable housing can be attached to each of the first electrode, the second electrode, and the third electrode. In some embodiments, the first afferent peripheral nerve is the tibial nerve, and the second afferent peripheral nerve is the saphenous nerve.
Also disclosed herein is a system of treating urinary symptoms in a patient, the system including any number of the following: a first pair of electrodes comprising an anode and a cathode and configured to be positioned at a first location on a skin surface relative to a first afferent peripheral nerve; a second pair of electrodes comprising an anode and a cathode and configured to be positioned at a second location on the skin surface relative to a second afferent peripheral nerve; a controller configured to deliver a first stimulus to the first peripheral nerve through the first pair of electrodes; and a second stimulus to the second peripheral nerve through the pair of second electrodes to modify at least one brain or spinal cord autonomic feedback loop relating to bladder function. The first pair of electrodes and second pair of electrodes can be configured to be positioned such that electric fields between the first pair of electrodes pass through the first peripheral nerve, and electric fields between the second pair of electrodes pass through the second peripheral nerve.
In some embodiments, disclosed herein is a wearable device for treating urinary symptoms in a patient. The device can include any number of the following: a controller; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a first afferent nerve pathway associated with bladder function; and a second peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a second afferent nerve pathway associated with bladder function; and at least one input source configured to provide feedback information. The controller can include a processor and a memory for receiving the real-time feedback information from the input source that, when executed by the processor, cause the device to adjust one or more parameters of a first electrical stimulus based at least in part on the feedback information; adjust one or more parameters of a second electrical stimulus based at least in part on the feedback information independent from the first electrical stimulus; deliver the first electrical stimulus to a first afferent nerve pathway through the first peripheral nerve effector to reduce urinary symptoms by modifying a first brain or spinal cord autonomic feedback loop relating to bladder function; and deliver the second electrical stimulus to a second afferent nerve pathway through the second peripheral nerve effector to reduce urinary symptoms by modifying a second brain or spinal cord autonomic feedback loop relating to bladder function. Adjusting the one or more parameters of the first electrical stimulus and the second electrical stimulus can contribute to balancing sympathetic and parasympathetic nervous system activity.
In some embodiments, systems and methods can include a wearable device with an electrically conductive skin interface that excite the underlying nerves from a transcutaneous surface stimulator. The device may be sized for a range of user sizes with stimulation electrodes positioned to target the appropriate nerves, as in the device described in, for example, U.S. Pat. No. 9,452,287 to Rosenbluth et al., PCT Pub. No. WO 2015/187712 to Wong et al., and PCT App. No. PCT/US2016/037080, each of which is incorporated by reference in their entireties.
This invention describes, in some embodiments, a wearable system that uses transcutaneous sensory stimulation in order to improve symptoms of overactive bladder and urinary incontinence. In some embodiments, key factors of this system enable chronic, home-use to improve the efficacy of peripheral nerve stimulation by avoiding the inconvenience of frequent office visits and invasive aspects of using percutaneous tibial neuromodulation or sacral nerve stimulation. Some embodiments can advantageously utilize transcutaneous neuromodulation of peripheral afferent nerve pathways to non-invasively affect brain or spinal cord pathways associated with physiologic regulation, such as bladder function.
Chronic peripheral nerve stimulation in a wearable form that can be integrated easily into an individual's life, allowing full mobility and ease of use, can improve the efficacy of urinary neuromodulation. However, home use of a percutaneous system can be inconvenient and technically difficult for the patient. Transcutaneous neuromodulation is a more suitable modality for home use but is currently limited by the form factor depending on the needs for chronic daily use. Furthermore, adding aspects of responsiveness and more frequent use could greatly improve the effectiveness and comfort of such a chronic use device.
The effects of peripheral nerve stimulation on bladder function may occur only during the period of active stimulation or may outlast the stimulation period after stimulation has ceased. Different mechanisms such as the modulation of urinary reflexes or induction of brain or spinal plasticity can be responsible for these experimental and clinical observations. Furthermore, the onset of the effects of stimulation may occur acutely (e.g., during or immediately following therapy) or only after several stimulation sessions in a chronic manner. For example, the effect of transcutaneous tibial and/or saphenous nerve stimulation on patient related outcomes is estimated to be up to 4-6 weeks after the initiation of weekly stimulation sessions. Depending on the underlying mechanisms and the time course of beneficial effects, stimulation may require delivery in a continuous fashion such as in sacral nerve stimulation, in discrete scheduled sessions such as once per day, or in an on-demand, conditional manner. Conditional stimulation may either rely on patient control to identify the sense of urinary urge or automated detection of an involuntary detrusor contraction (IDC) which is responsible for urgency symptoms or evolution to frank incontinence.
Several peripheral nerves can be selected as targets for urinary neuromodulation, including the tibial, pudendal, and dorsal genital nerve, with demonstrated acute and chronic effects on bladder function in animal and human experimental studies. The saphenous nerve can acutely reduce bladder hyperexcitability. The saphenous nerve is a purely sensory nerve that innervates the skin on the medial lower leg. Its proximity to the skin surface makes it an advantageous target for transcutaneous stimulation. Selective stimulation of the tibial and saphenous nerve can reduce symptoms of overactive bladder. In some embodiments, disclosed herein is a wearable device for inducing neural plasticity in a user with transcutaneous electrical stimulation of an afferent peripheral nerve. The device can include any number of a controller; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a first afferent peripheral nerve; and at least one biomedical sensor or data input source configured to provide feedback information. The controller can include a processor and a memory for receiving the feedback information from the sensor, that when executed by the processor, cause the device to adjust one or more parameters of a first electrical stimulus based at least in part on the feedback information; and/or deliver the first electrical stimulus to the first afferent peripheral nerve to the first peripheral nerve effector. The first electrical stimulus can include patterned, such as burst (e.g., theta burst) electrical stimulation configured to induce neural plasticity. The stimulation can be continuous, intermittent, or intermediate theta burst stimulation in some embodiments. The device can also be configured to deliver a priming electrical nerve stimulation signal prior to the first electrical stimulation signal, which can be a non-theta burst stimulation signal. The device can further include a second peripheral nerve effector, including at least one stimulation electrode configured to be positioned to transcutaneously modulate a second afferent peripheral nerve, and is configured to deliver a second electrical nerve stimulation signal transcutaneously to the afferent peripheral nerve of the user. The signal can include, for example, electrical theta burst stimulation. Also disclosed herein is a method for treating overactive bladder, that can include assessing at least one of sympathetic and parasympathetic activity of a subject and determining the presence of sympathetic or parasympathetic overactivity in the subject; and not to be limited by theory, stimulating the saphenous nerve sufficient to have a therapeutic effect on overactive bladder if abnormal sympathetic activity is present; and/or stimulating the tibial nerve sufficient to have a therapeutic effect on overactive bladder if abnormal parasympathetic activity is present. In some embodiments, stimulating comprises only electrical transcutaneous stimulation. The stimulation can include inhibiting or exciting nerve activity of either or both of the saphenous nerve, tibial nerve, sacral nerve, peroneal nerve, or other target nerves. Sympathetic and parasympathetic activity of a subject can include measuring heart rate variability (HRV), such as via a wrist-worn device. Other parameters such as heart rate and electrodermal activity can be measured in addition or alternatively. HRV can be measured during a bladder filling procedure, such as urodynamic cystography, either prior to and/or after the initial stimulation. Also disclosed herein in some embodiments is a method for treating overactive bladder, that can include electrically stimulating a first nerve associated with bladder function; assessing at least one of sympathetic and parasympathetic activity of a subject and determining the presence or absence of sympathetic or parasympathetic overactivity in the subject; assessing symptomatology of overactive bladder; and adjusting the electrical stimulation based upon assessing the at least one of sympathetic and parasympathetic activity and the symptomatology of overactive bladder. Adjusting the electrical stimulation can include, for example, identifying sympathetic or parasympathetic overactivity in the patient, and adjusting the frequency of stimulation of the first nerve; and/or discontinuing electrical stimulation of the first nerve associated with bladder function; and initiating electrical stimulation of a second nerve associated with bladder function. In some embodiments, the first electrical stimulation includes a randomized stimulation parameter including one or more of: pulse width, frequency, and amplitude.
In some embodiments, also disclosed herein is method of treating urinary symptoms in a patient with dual transcutaneous stimulation of a first afferent lower extremity nerve and a second afferent lower extremity nerve. The method can include any number of the following: positioning a first peripheral nerve effector on the patient's skin to stimulate the first afferent lower extremity nerve of the patient; positioning a second peripheral nerve effector on the patient's skin to stimulate the second afferent lower extremity nerve of the patient; delivering a first electrical nerve stimulation signal transcutaneously to the first afferent lower extremity nerve through the first peripheral nerve effector; delivering a second electrical nerve stimulation signal transcutaneously to the second afferent lower extremity nerve through the second peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. The method does or does not in some cases utilize any implantable components. In some embodiments, the method involves transcutaneous stimulation. The first electrical stimulation signal and the second electrical stimulation signal can include burst electrical stimulation signals, wherein the burst electrical stimulation signals induce neural plasticity. The burst stimulation signals can include, for example, alpha, delta, or theta burst stimulation, e.g., continuous, intermittent, or intermediate theta burst stimulation. The first electrical stimulation can include a stimulation parameter modulated within a range from a first lower predetermined value to a second higher predetermined value, wherein the stimulation parameter is selected from the group consisting of pulse width, frequency, and amplitude. The first peripheral nerve effector can be physically connected, or not physically connected to the second peripheral nerve effector. The first electrical stimulation signal can be stimulatory or inhibitory to the first afferent lower extremity peripheral nerve. In some cases, the first electrical stimulation signal can be stimulatory to the first afferent lower extremity peripheral nerve, and the second electrical stimulatory signal can be inhibitory to the second afferent lower extremity peripheral nerve. The method can also include delivering a priming electrical nerve stimulation signal prior to the first electrical stimulation signal. The priming electrical nerve stimulation signal can be a non-theta burst stimulation signal. The method can also include alternating the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve and the second peripheral nerve signal to the second afferent lower extremity peripheral nerve. The first afferent lower extremity peripheral nerve can be, for example, one of the saphenous nerve and a tibial nerve. The method can treat a variety of conditions, including overactive bladder, nocturia, or stress incontinence of the user. The method can also include delivering brain stimulation to induce oscillatory activity in the brain; and synchronizing the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve with the oscillatory activity in the brain. The method can also include delivering noninvasive transcranial direct current stimulation or noninvasive transcranial magnetic stimulation to the brain; and synchronizing the transcranial stimulation with the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve. The method can further include delivering a priming stimulus prior to the first electrical stimulation signal. Delivering the priming stimulus can include delivering noninvasive transcranial direct current stimulation and/or noninvasive transcranial magnetic stimulation to the brain. The first peripheral nerve effector and the second peripheral nerve effector can be both positioned below the knee of the patient and/or above the ankle of the patient. The first electrical stimulation signal can be the same as, or different from the second electrical stimulation signal. The first electrical stimulation signal has a first frequency, pulse width, amplitude, and/or other parameter different from a second parameter of the second electrical stimulation signal. The first frequency can be in some cases from about 5 Hz to about 30 Hz. The second frequency can be in some cases from about 10 Hz to about 20 Hz. Receiving an input relating to autonomic nervous system activity of the patient an include receiving data from a sensor that measures autonomic nervous system activity of the patient, such as heart rate variability of the patient. Heart rate variability data can be received from an optical sensor measuring blood flow characteristics and disposed proximate a vessel proximate a knee of the patient. Data can also be received from a sensor that measures galvanic skin response of the patient. The input could also be urinary symptoms of the patient, and/or nocturia episodes of the patient.
Also disclosed in some embodiments is a wearable device for dual transcutaneous stimulation of a first afferent lower extremity nerve and a second afferent lower extremity nerve and for treating urinary symptoms in a patient. The device could include any of the following: a controller; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate the saphenous nerve; a second peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate the tibial nerve; and at least one biomedical sensor or data input source configured to provide feedback information. The controller can include a processor and a memory for receiving the feedback information from the sensor that, when executed by the processor, cause the device to: adjust one or more parameters of a first electrical stimulus and a second electrical stimulus based at least in part on the feedback information; and/or deliver the first electrical stimulus to the first afferent lower extremity nerve through the first peripheral nerve effector and deliver the second electrical stimulus to the second afferent lower extremity nerve through the second peripheral nerve effector to reduce urinary symptoms by modifying a brain or spinal cord autonomic feedback loop relating to bladder function and balancing sympathetic nerve and parasympathetic nerve activity. The device could be, or in some cases not configured for implantation within the patient. The first electrical stimulus and the second electrical stimulus can both include burst stimulation, such as, for example, continuous, intermittent, and/or intermediate theta burst stimulation. The first peripheral nerve effector may not in some cases be physically connected to the second peripheral nerve effector. The first electrical stimulus could be stimulatory or inhibitory to the first afferent lower extremity peripheral nerve. In some cases, the first electrical stimulation signal is stimulatory to the first afferent lower extremity peripheral nerve, and the second electrical stimulatory signal is inhibitory to the second afferent lower extremity peripheral nerve. The device could be further configured to deliver a priming electrical nerve stimulus prior to delivering the first electrical stimulus, such as a non-theta burst stimulus. The device can also be further configured to alternate the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve and the second peripheral nerve signal to the second afferent lower extremity peripheral nerve. The feedback information can in some cases be real-time feedback information. The first electrical stimulus can have a frequency of, for example, between about 5 Hz and about 30 Hz. The second electrical stimulus can have a frequency of, for example, between about 10 Hz and about 20 Hz. The feedback information could include any number of: autonomic nervous system activity of the patient; heart rate variability; nocturia events of the patient; and/or information relating to patient sleep state.
In some embodiments, disclosed herein is a method of treating urinary symptoms in a patient with dual transcutaneous stimulation of a first afferent lower extremity nerve and a second afferent lower extremity nerve. The method can include providing a wearable device including any number of elements disclosed herein; positioning the first peripheral nerve effector on the patient's skin to stimulate the first afferent lower extremity nerve of the patient; positioning the second peripheral nerve effector on the patient's skin to stimulate the second afferent lower extremity nerve of the patient; delivering a first electrical nerve stimulation signal transcutaneously to the saphenous nerve through the first peripheral nerve effector; delivering a second electrical nerve stimulation signal transcutaneously to the tibial nerve through the second peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. In some embodiments, the method does not utilize any implantable components, and only involves transcutaneous stimulation. The first electrical stimulation signal and the second electrical stimulation signal can include burst electrical stimulation signals, wherein the burst electrical stimulation signals induce neural plasticity. In some embodiments, use of a device including any number of features disclosed herein can modify at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient and induce neural plasticity in the patient.
Also disclosed herein is a wearable system for treating urinary symptoms in a patient. The device can include any number of: a first controller and a second controller configured to operably communicate with each other, the first controller and the second controller not in physical communication with each other; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a first afferent nerve pathway associated with bladder function; a second peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a second afferent nerve pathway associated with bladder function; and at least one input source configured to provide feedback information. The first controller and the second controller each can include a processor and a memory for receiving the real-time feedback information from the input source that, when executed by the processor, cause the device to: adjust one or more parameters of a first electrical stimulus based at least in part on the feedback information; adjust one or more parameters of a second electrical stimulus based at least in part on the feedback information independent from the first electrical stimulus; deliver the first electrical stimulus to a first afferent nerve pathway through the first peripheral nerve effector to reduce urinary symptoms by modifying a first brain or spinal cord autonomic feedback loop relating to bladder function; and/or deliver the second electrical stimulus to a second afferent nerve pathway through the second peripheral nerve effector to reduce urinary symptoms by modifying a second brain or spinal cord autonomic feedback loop relating to bladder function. Adjusting the one or more parameters of the first electrical stimulus and the second electrical stimulus can contribute to balancing sympathetic and parasympathetic nervous system activity. The first electrical stimulus and the second electrical stimulus both can include burst stimulation.
In some embodiments, also disclosed herein is a method of treating urinary symptoms in a patient with dual transcutaneous stimulation of a first afferent lower extremity nerve and a second afferent lower extremity nerve. The method can include any number of: positioning a first peripheral nerve effector on the patient's skin to stimulate the first afferent lower extremity nerve of the patient; positioning a second peripheral nerve effector on the patient's skin to stimulate the second afferent lower extremity nerve of the patient; delivering a first electrical nerve stimulation signal transcutaneously to the first afferent lower extremity nerve through the first peripheral nerve effector; delivering a second electrical nerve stimulation signal transcutaneously to the second afferent lower extremity nerve through the second peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient, wherein the input comprises both heart rate variability and electrodermal activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. The heart rate variability and electrodermal activity inputs can be received from a wrist-worn device on the patient, a device on the patient's lower extremity, from an ear-worn device, or other site. The first electrical stimulus and the second electrical stimulus can both include burst stimulation, such as, for example, continuous, intermittent, and/or intermediate theta burst stimulation. The first peripheral nerve effector may not in some cases be physically connected to the second peripheral nerve effector. The first electrical stimulus could be stimulatory or inhibitory to the first afferent lower extremity peripheral nerve. In some cases, the first electrical stimulation signal is stimulatory to the first afferent lower extremity peripheral nerve, and the second electrical stimulatory signal is inhibitory to the second afferent lower extremity peripheral nerve. The device could be further configured to deliver a priming electrical nerve stimulus prior to delivering the first electrical stimulus, such as a non-theta burst stimulus. The device can also be further configured to alternate the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve and the second peripheral nerve signal to the second afferent lower extremity peripheral nerve. The feedback information can in some cases be real-time feedback information. The first electrical stimulus can have a frequency of, for example, between about 5 Hz and about 30 Hz. The second electrical stimulus can have a frequency of, for example, between about 10 Hz and about 20 Hz. The feedback information could include any number of: autonomic nervous system activity of the patient; heart rate variability; nocturia events of the patient; and/or information relating to patient sleep state.
In some embodiments, also disclosed herein is a wearable device for dual transcutaneous stimulation of a first afferent lower extremity nerve and a second afferent lower extremity nerve and for treating urinary symptoms in a patient. The device can include a controller; a first peripheral nerve effector that includes at least one stimulation electrode configured to be positioned to transcutaneously modulate the first afferent lower extremity nerve; a second peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate the second afferent lower extremity nerve; and at least one biomedical sensor or data input source configured to provide feedback information, the feedback information comprising autonomic nervous system activity comprising both heart rate variability information and electrodermal activity information of the patient. The controller can include a processor and a memory for receiving the feedback information from the sensor that, when executed by the processor, cause the device to adjust one or more parameters of a first electrical stimulus and a second electrical stimulus based at least in part on the feedback information; and/or deliver the first electrical stimulus to the first afferent lower extremity nerve through the first peripheral nerve effector and deliver the second electrical stimulus to the second afferent lower extremity nerve through the second peripheral nerve effector to reduce urinary symptoms by modifying a brain or spinal cord autonomic feedback loop relating to bladder function and balancing sympathetic nerve and parasympathetic nerve activity. The device can be configured for implantation within the patient. The first electrical stimulus and the second electrical stimulus can both include burst stimulation, such as, for example, continuous, intermittent, and/or intermediate theta burst stimulation. The first peripheral nerve effector may not in some cases be physically connected to the second peripheral nerve effector. The first electrical stimulus could be stimulatory or inhibitory to the first afferent lower extremity peripheral nerve. In some cases, the first electrical stimulation signal is stimulatory to the first afferent lower extremity peripheral nerve, and the second electrical stimulatory signal is inhibitory to the second afferent lower extremity peripheral nerve. The device could be further configured to deliver a priming electrical nerve stimulus prior to delivering the first electrical stimulus, such as a non-theta burst stimulus. The device can also be further configured to alternate the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve and the second peripheral nerve signal to the second afferent lower extremity peripheral nerve. The feedback information can in some cases be real-time feedback information. The first electrical stimulus can have a frequency of, for example, between about 5 Hz and about 30 Hz. The second electrical stimulus can have a frequency of, for example, between about 10 Hz and about 20 Hz. The feedback information could include any number of: autonomic nervous system activity of the patient; heart rate variability; nocturia events of the patient; and/or information relating to patient sleep state.
Also disclosed herein in some embodiments is a method of treating urinary symptoms in a patient with dual stimulation of a first afferent lower extremity nerve and a second afferent lower extremity nerve. The method can include any of the following: positioning a first peripheral nerve effector on the patient to stimulate the first afferent lower extremity nerve of the patient; positioning a second peripheral nerve effector on the patient to stimulate the second afferent lower extremity nerve of the patient; delivering a first electrical nerve stimulation signal to the first afferent lower extremity nerve through the first peripheral nerve effector; delivering a second electrical nerve stimulation signal to the second afferent lower extremity nerve through the second peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. In some embodiments, the first electrical stimulation signal and the second electrical stimulation signal comprise burst electrical stimulation signals. The burst electrical stimulation signals can induce neural plasticity.
Also disclosed herein in some embodiments of a method for treating overactive bladder. The method can include any of the following: assessing at least one of sympathetic and parasympathetic activity of a subject and determining the presence of sympathetic or parasympathetic overactivity in the subject; stimulating a first lower extremity afferent nerve sufficient to have a therapeutic effect on overactive bladder only if abnormal sympathetic activity is present; and stimulating a second lower extremity afferent nerve sufficient to have a therapeutic effect on overactive bladder only if abnormal parasympathetic activity is present. Stimulating can include only electrical transcutaneous stimulation in some cases. Stimulating can involve exciting and/or inhibiting nerve activity of the first lower extremity afferent nerve or the second lower extremity afferent nerve. In some embodiments, the second lower extremity afferent nerve can be on a different (e.g., contralateral) extremity with respect to the first lower extremity afferent nerve. Stimulating can involve exciting nerve activity of the first lower extremity afferent nerve or the second lower extremity afferent nerve if one or both abnormal sympathetic activity and abnormal parasympathetic activity are present. Assessing at least one of sympathetic and parasympathetic activity of a subject can include measuring HRV in the subject, such as via a wrist-worn or other device. The method can also include measuring heart rate, and/or electrodermal activity in the subject. HRV can be measured during a bladder filling procedure, e.g., urodynamic cystography, which can be performed prior to or after the initial stimulation.
Also disclosed herein is a method for treating overactive bladder, including any number of electrically stimulating a first nerve associated with bladder function; assessing at least one of sympathetic and parasympathetic activity of a subject and determining the presence or absence of sympathetic or parasympathetic overactivity in the subject; assessing symptomatology of overactive bladder; and/or adjusting the electrical stimulation based upon assessing the at least one of sympathetic and parasympathetic activity and the symptomatology of overactive bladder. Adjusting the electrical stimulation can include identifying sympathetic or parasympathetic overactivity in the patient; discontinuing electrical stimulation of the first nerve associated with bladder function; and/or initiating electrical stimulation of a second nerve associated with bladder function. The first and/or second nerve could be, for example, the saphenous, tibial, peroneal, or sacral nerves. Stimulating can include, for example, only electrical transcutaneous stimulation. Assessing at least one of sympathetic and parasympathetic activity of a subject can include measuring HRV in the subject, such as via a wrist-worn device. The method can also include measuring heart rate and/or electrodermal activity in the subject. HRV can be measured during a bladder filling procedure, e.g., urodynamic cystography, which can be performed prior to or after the initial stimulation.
Disclosed herein is a method of treating urinary symptoms in a patient with transcutaneous stimulation of an afferent lower extremity nerve. The method can include, for example, positioning a first peripheral nerve effector on the patient's skin to stimulate the afferent lower extremity nerve of the patient; delivering a first electrical nerve stimulation signal transcutaneously to the afferent lower extremity nerve through the first peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. The method can in some cases not utilize any implantable components, and only involves transcutaneous stimulation. The first electrical stimulation signal can include burst electrical stimulation signals that can induce neural plasticity.
The stimulation can be continuous, intermittent, or intermediate theta burst stimulation in some embodiments. The device can also be configured to deliver a priming electrical nerve stimulation signal prior to the first electrical stimulation signal, which can be a non-theta burst stimulation signal. The device can further include a second peripheral nerve effector, including at least one stimulation electrode configured to be positioned to transcutaneously modulate a second afferent peripheral nerve, and is configured to deliver a second electrical nerve stimulation signal transcutaneously to the afferent peripheral nerve of the user. The signal can include, for example, electrical theta burst stimulation. Also disclosed herein is a method for treating overactive bladder, that can include assessing at least one of sympathetic and parasympathetic activity of a subject and determining the presence of sympathetic or parasympathetic overactivity in the subject; and stimulating the saphenous nerve sufficient to have a therapeutic effect on overactive bladder if abnormal sympathetic activity is present; and/or stimulating the tibial nerve sufficient to have a therapeutic effect on overactive bladder if abnormal parasympathetic activity is present. In some embodiments, stimulating comprises only electrical transcutaneous stimulation. The stimulation can include inhibiting or exciting nerve activity of either or both of the saphenous nerve, tibial nerve, or other target nerves. Sympathetic and parasympathetic activity of a subject can include measuring HRV, such as via a wrist-worn device. Other parameters such as heart rate and electrodermal activity can be measured in addition or alternatively. HRV can be measured during a bladder filling procedure, such as urodynamic cystography, either prior to and/or after the initial stimulation. Also disclosed herein in some embodiments is a method for treating overactive bladder, that can include electrically stimulating a first nerve associated with bladder function; assessing at least one of sympathetic and parasympathetic activity of a subject and determining the presence or absence of sympathetic or parasympathetic overactivity in the subject; assessing symptomatology of overactive bladder; and adjusting the electrical stimulation based upon assessing the at least one of sympathetic and parasympathetic activity and the symptomatology of overactive bladder. Adjusting the electrical stimulation can include, for example, identifying sympathetic or parasympathetic overactivity in the patient, and adjusting the frequency of stimulation of the first nerve; and/or discontinuing electrical stimulation of the first nerve associated with bladder function; and initiating electrical stimulation of a second nerve associated with bladder function. In some embodiments, the method can also include delivering noninvasive transcranial direct current stimulation or noninvasive transcranial magnetic stimulation to the brain; and synchronizing the transcranial stimulation with the first electrical nerve stimulation signal to the first afferent lower extremity peripheral nerve, and/or delivering a priming stimulus prior to the first electrical stimulation signal, including delivering noninvasive transcranial direct current stimulation or noninvasive transcranial magnetic stimulation to the brain. The first peripheral nerve effector can be positioned below the knee of the patient, but above the ankle of the patient. Receiving an input relating to autonomic nervous system activity of the patient can include, for example, receiving data from a sensor that measures autonomic nervous system activity, heart rate variability, activity (e.g., number of steps taken and/or distance walked) and/or galvanic skin response of the patient. Heart rate variability data can be received from an optical sensor measuring blood flow characteristics and disposed proximate a vessel proximate a knee of the patient. An input can also include data relating to urinary symptoms, activity, and/or nocturia episodes of the patient.
In some embodiments, disclosed herein is a wearable device for transcutaneous stimulation of a first afferent lower extremity nerve for treating urinary symptoms in a patient. The device can include a controller; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a first afferent lower extremity nerve; and a stimulator configured to deliver a first electrical stimulus to the first afferent lower extremity nerve through the first peripheral nerve effector to reduce urinary symptoms by modifying a brain or spinal cord autonomic feedback loop relating to bladder function and balancing sympathetic nerve and parasympathetic nerve activity. The device is in some embodiments not configured for implantation within the patient. The first electrical stimulus can include burst stimulation, such as alpha, delta, or theta burst stimulation, e.g., intermittent, intermediate, and/or continuous theta burst stimulation. The device can also include one or more biomedical sensors or data input sources configured to provide feedback information. The controller can include a processor and a memory for receiving the feedback information from the sensor that, when executed by the processor, cause the device to adjust one or more parameters of the first electrical stimulus based at least in part on the feedback information. The first electrical stimulation can include a stimulation parameter modulated within a range from a first lower predetermined value to a second higher predetermined value. The stimulation parameter can include one or more of, for example, pulse width, frequency, and amplitude. The first electrical stimulus can be stimulatory or inhibitory to the first afferent lower extremity peripheral nerve. The device can be further configured to deliver a priming electrical nerve stimulus prior to delivering the first electrical stimulus, such as a non-theta burst stimulus. The feedback information can include real-time feedback information. The first or second electrical stimulus could have, for example, a frequency of between about 5 Hz and about 30 Hz. The feedback information could include autonomic nervous system activity, heart rate variability, nocturia events of the patient, and/or patient sleep state.
In some embodiments, disclosed herein is a wearable system for treating urinary symptoms in a patient. The device can include any number of a first controller and a second controller configured to operably communicate with each other, the first controller and the second controller not in physical communication with each other; a first peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate a first afferent nerve pathway associated with bladder function; a second peripheral nerve effector, comprising at least one stimulation electrode configured to be positioned to transcutaneously modulate the first afferent nerve pathway associated with bladder function; at least one input source configured to provide feedback information; and/or a stimulator configured to deliver the first electrical stimulus to a first afferent nerve pathway through the first peripheral nerve effector to reduce urinary symptoms by modifying a first brain or spinal cord autonomic feedback loop relating to bladder function; and deliver the second electrical stimulus to the first afferent nerve pathway through the second peripheral nerve effector to reduce urinary symptoms by modifying the first brain or spinal cord autonomic feedback loop relating to bladder function. Adjusting the one or more parameters of the first electrical stimulus and the second electrical stimulus can contribute to balancing sympathetic and parasympathetic nervous system activity. The first electrical stimulus and the second electrical stimulus can both include burst stimulation. The first controller and the second controller can each include a processor and a memory for receiving the real-time feedback information from the input source that, when executed by the processor, cause the device to adjust one or more parameters of the first electrical stimulus based at least in part on the feedback information and/or adjust one or more parameters of the second electrical stimulus based at least in part on the feedback information independent from the first electrical stimulus. The input source can include, for example, at least one biomedical sensor. Feedback information can include, for example, autonomic nervous system activity of the patient, heart rate variability information of the patient, nocturia events of the patient, patient sleep state, or patient eye blink reflex.
As used herein, the terms “stimulating” and “stimulator” generally refer to delivery of a signal, stimulus, or impulse to neural tissue of the targeted region. The effect of such stimulation on neuronal activity is termed “modulation;” however, for simplicity, the terms “stimulating” and “modulating,” and variants thereof, are sometimes used interchangeably herein. The effect of delivery of the signal to the neural tissue may be excitatory or inhibitory and may potentiate acute and/or long-term changes in neuronal activity. For example, the effect of “stimulating” or “modulating” a neural tissue may comprise one or more of the following effects: (a) depolarizing the neurons such that the neurons fire action potentials, (b) hyperpolarizing the neurons to inhibit action potentials and optionally anode break excitation following termination of a hyperpolarizing event, (c) depleting neurons ion stores to inhibit firing action potentials, (d) altering with sensory input, including proprioception, (e) influencing muscle contractions, (f) affecting changes in neurotransmitter release or uptake, or (g) inhibiting firing. “Sensory input” refers to receptors, nerves, and/or neurons that transmit sensory information to other nerves, the spinal cord, brain, or central nervous system. “Proprioception” refers to one's sensation of the relative position of one's own body parts or the effort being employed to move one's body part. Proprioception may otherwise be referred to as somatosensory, kinesthetic, or haptic sensation. A “proprioceptor” is a receptor providing proprioceptive information to the nervous system and includes stretch receptors in muscles, joints, ligaments, and tendons as well as receptors for pressure, temperature, light and sound. An “effector” is the mechanism by which the device modulates the target nerve. For example, the “effector” may be electrical stimulation of the nerve or mechanical stimulation of proprioceptors.
“Electrical stimulation” refers to the application of electrical signals to the soft-tissue and nerves of the targeted area. The “cloud” refers to a network of computers communication using real-time protocols such as the internet to analyze, display and interact with data across distributed devices.
Some forms of therapy for control of urinary symptoms include electrical neuromodulation, including transcutaneous and/or percutaneous peripheral nerve stimulation and/or implantable pudendal or sacral nerve stimulation. Neuromodulation of the urinary system can be highly effective in the control of lower urinary tract symptoms. Modulation of urinary reflexes can be accomplished in some embodiments by stimulation of lumbosacral afferent pathways. Sacral neuromodulation can include surgical placement of an implant at the level of the S3 sacral foramina and can be highly effective and durable but requires an invasive procedure. The stimulation can be performed continuously and in an open-loop. Sacral stimulation can lead to modulation of the micturition reflex at the spinal or supraspinal level. Although sacral nerve stimulation is considered relatively long-lasting, it is invasive and side effects include buttock, lower extremity or pelvic pain, lead site infection, and negative changes in urinary, bowel or sexual function. Device related complications include battery failure, lead migration, or loss of efficacy necessitating revision or explanation of the device.
Modulation of bladder dysfunction can also be achieved in some cases using intermittent tibial nerve stimulation. The acute effects of stimulation can include improvements in cystometry measures, including bladder capacity. Stimulation can be performed, for example, weekly with a percutaneous needle electrode in 30 minute sessions. As the stimulation is not continuous, there can be a carry-over effect. The effects of percutaneous tibial nerve stimulation can be maintained after, for example, 12 weeks, but a continued schedule of sessions can be required thereafter every month to maintain efficacy. Stimulation of the tibial nerve can lead to spinal root L4-S3 stimulation inhibiting bladder activity although it is unclear whether spinal reflex or brain networks are responsible for the effects. The presence of a carry-over effect after the period of stimulation suggests a plasticity mechanism either at the level of the spine or brain.
Transcutaneous stimulation of one, two, or more target nerves of interest, e.g., the saphenous nerve, and/or or tibial nerve stimulation can control urinary incontinence symptoms with varying levels of success. However, in some embodiments, transcutaneous stimulation can be preferred. The feasibility of home-based stimulation has been limited by device form factor and limited programming flexibility of current devices.
In some embodiments, more continuous stimulation at the level of the tibial and/or saphenous nerve can potentially improve the efficacy of peripheral nerve stimulation for conditions such as, for example, urinary incontinence. An implanted percutaneous tibial nerve stimulator can be efficacious and safe. Some embodiments can use frequencies of, for example, between about 1 kHz and about 100 kHz, 1 Hz and about 100 Hz, between about 1 Hz and about 50 Hz, between about 5 Hz and about 30 Hz, or between about 10 Hz and about 20 Hz stimulation for a specified period of time, such as about, at least about, or no more than about 20, 30, 40, 50 or 60 minutes at a sensory or sub-sensory threshold or below motor contraction threshold that is tolerable to the patient. Varying the regularity of stimulation and the frequency of the stimulation waveform may improve tolerance or efficacy in some cases. An increased frequency of stimulation may be more effective but could require a more chronic at-home portable system to provide continuous transcutaneous stimulation throughout the day.
Stimulating at intensities below the sensory threshold or with high frequencies (e.g., between about 1 kHz to about 100 kHz) can avoid the discomfort (tingling, numbness, pain) that can be associated with peripheral nerve stimulation. Because the exact electrode position, size and surface contact have a large effect on the stimulation level and the anatomical structures that receive the stimulation, the sensory threshold may need to be calibrated for each patient and even for each session. This calibration may be done by the user manually setting the stimulation parameters or otherwise indicating their sensory threshold. Another possible embodiment is for the device to automatically sweep through a range of stimulation parameters and the patient chooses the most comfortable set of parameter values. Another possible embodiment is for the patient to choose from among a set of previously chosen parameter values that provided effective and comfortable stimulation.
In some embodiments, disclosed herein are peripheral nerve stimulators to improve conditions including but not limited to urinary dysfunction. The stimulation can target one, two, three, or more nerves associated with bladder function. The nerves can include, for example, the tibial nerve or posterior tibial nerve, which can branch into the medial and lateral plantar nerve branches, and the calcaneal nerves. The saphenous nerve is the cutaneous branch of the femoral nerve. Other nerves include, for example, the pudendal nerve, pelvic nerve, dorsal genital nerve, external anal sphincter nerve, and the dorsal genital nerve, for example. In some embodiments, the tibial (e.g., posterior tibial) nerve can be stimulated transcutaneously in a manner similar to percutaneous tibial nerve stimulation but noninvasively and in a more prolonged manner. In some embodiments, systems and methods include only transcutaneous elements without any implanted and/or percutaneous components. In some embodiments, the nerve(s) to be stimulated are lower extremity peripheral afferent nerves only, and are not spinal nerves.
Not to be limited by theory, voluntary control of the bladder can be mediated in large part by the autonomic nervous system (ANS). The ANS maintains a balance which can be important to the normal functioning of the body's organs. For instance, the hypogastric nerve (sympathetic) and pelvic nerve (parasympathetic) both carry information about bladder fullness to the brain, and also work together to enable the relaxation-contraction mechanism that controls micturition.
Activation of the pontine micturition center (PMC) results in parasympathetic activation of the bladder. This in turn contracts muscles in the bladder and relaxes muscles in the urethra. Micturition commands cease when CNS structures including the periaqueductal gray (PAG) receive signals that the bladder is no longer full.
Inappropriate activation and inhibition of the parasympathetic and sympathetic systems can result in a sense of bladder fullness, urgency, sensory discomfort, and/or involuntary voiding. Peripheral stimulation that affects the activity of autonomic nerves can be used to modulate or interrupt micturition reflex circuits to correct abnormal bladder functioning. This modulation can be achieved by, for example, stimulation of the saphenous nerve, tibial nerve, or a combination of the two. In some embodiments, systems and methods use stimulation schemes designed to dephase, override or obscure the abnormal networks. In some embodiments, systems and methods use stimulation schemes designed to restore balance of sympathetic and parasympathetic activity of the micturition reflex loop. Advantageously, certain embodiments utilize transcutaneous afferent stimulation of one, two, or more peripheral nerves to modulate a brain or spinal pathway associated with bladder function, and/or an organ or target remote from the site(s) of stimulation.
Generally, sympathetic fibers originate in the T11 to L2 segments of the spinal cord, while parasympathetic fibers originate in the S2 to S4 spinal segments. The sympathetic fibers travel through the hypogastric nerve and inferior mesenteric ganglia, while the parasympathetic fibers travel in the pelvic nerves and plexus. In some cases, effective frequency band for this parasympathetic modulation can be, for example, around the frequency band of 10 to 20 Hz, while the frequency band sympathetic modulation can be, in some cases, as high as 30 Hz or as low as 5 Hz. Not to be limited by theory, in some cases the higher frequencies may offer benefit in comfort while the lower frequencies may offer benefit in better preservation.
In some embodiments, systems and methods involve stimulation parameters including frequency and spatial selectivity on the surface of the distal limb to selectively modulate and balance the sympathetic and parasympathetic system.
Not to be limited by theory, stimulation of a first target nerve, such as the saphenous nerve can provide sympathetic modulation of the bladder circuit. Specifically, electrical stimulation tuned to excite large myelinated fibers in a target nerve, e.g., the saphenous nerve can provide somatic afferent input to the lumbar plexus, mediating the sympathetic input to the bladder circuitry via the hypogastric nerve. Sympathetic nerves relax the detrusor muscle of the bladder by releasing norepinephrine, activating the β adrenergic receptors, and contract the intrinsic urethral sphincter, by activating the α-adrenergic receptors. Relaxing the bladder and contracting the intrinsic sphincters can give comfort during the filling and storage phases of the bladder cycle. Stimulation of a second target nerve, e.g., the tibial nerve can provide parasympathetic modulation of the bladder circuit. Specifically, electrical stimulation tuned to excite large myelinated fibers in the tibial nerve provides somatic afferent input to sacral plexus, the sacral micturition center, mediating parasympathetic input to the bladder circuitry via the pelvic nerves via release of cholinergic transmitters. There may also be input from the somatic efferents of the pelvic floor to the external urethral sphincter and modulates the afferent sensation of bladder fullness. Due to widely connected and circuit-based mechanisms of these circuits, all mechanisms described above can in some embodiments modulate the central cortical and pontine micturition centers which coordinate and time signals.
The system may run on a selection of pre-specified programs that vary stimulation parameters and target one or more nerves individually or in combination to improve symptoms of overactive bladder in a specific patient, e.g. whether their challenge is primarily daytime urinary urgency, nighttime waking (nocturia), or incontinence. Alternatively, the system may be closed loop on a number of parameters including: the subject's symptomatic history, including night waking events, or manually entered urination indicated on board the device or a secondary device; direct detection of sympathetic and parasympathetic tone in the bladder or general circuitry, including HRV and galvanic skin response; and/or closed-loop based on previous usage of a device.
In some embodiments, nerve stimulation can be synergistically combined with one, two, or more pharmacologic therapies for overactive bladder, including but not limited to an anti-cholinergic (e.g., oxybutynin, tolterodine, trospium, darifenacin, solifenancin, and/or fesoterodine), a beta-3 adrenergic (e.g., mirabegron), an anti-spasmodic (e.g., flavoxate), and/or an anti-depressant (e.g., a tricyclic antidepressant such as desipramine or imipramine), a hormone (such as an estrogen and/or progesterone), or botulinum toxin.
Use of chronic, noninvasive stimulation can involve certain waveform characteristics to excite sensory neurons in a comfortable manner. The frequency of stimulation used can be, for example, within the between about 1 Hz and about 500 Hz range (such as, for example, between about 5 Hz and about 30 Hz, such as between about 10 Hz and about 20 Hz) or between about 1 kHz and about 100 kHz to preferentially affect the proper targets. In some embodiments, the waveforms can be biphasic rectangular or balanced in charge in order to minimize irritation to the skin, such as illustrated schematically in
In some embodiments, the effector can be excitatory to the nerve. In other embodiments, the effector can be inhibitory to the nerve. In some embodiments, the system can be used to excite the nerve during some portions of the treatment and inhibit the nerve during other portions of the treatment.
In some embodiments, waveforms including those described herein can be modified over time in order to minimize certain effects, such as habituation. One way of decreasing habituation is to modify the frequency, pulse width, amplitude, or burst pattern of the stimulation. For instance, randomizing or pseudo-randomizing parameters such as, for example, the frequency or pulse width can reduce habituation. Using a Gaussian distribution for randomization can be effective in some cases, and used in such waveforms as stochastic waveforms. Another way of reducing habituation is to the lower the frequency below a certain threshold, such as, for example, no more than about 60 Hz, 55 Hz, 50 Hz, 45 Hz, or 40 Hz, in which humans tend not to habituate.
Varying other parameters such as amplitude can be a way to improve waveform comfort. For example, the amplitude of the stimulation can be adjusted based on the threshold necessary to produce strong sensory perception and paresthesia without eliciting motor contraction. Excitation of muscles can lead to unpleasant cramping sensations in some embodiments. This amplitude could also be modulated throughout a session to be the appropriate, comfortable value depending a person's position or motion.
The stimulation waveforms described herein can be applied continuously to target nerves such as the tibial and/or saphenous nerves, for example, or can be provided in a manner that is adaptive in applying stimulation of various durations or by adjusting properties of the stimulation waveform, including but not limited to amplitude, frequency, and pulse width, in response to different inputs in the system. In some embodiments, the system could include closed loop control, using one or more signals measured by the device or feedback input into the device by the patient or physician to modulate the stimulation to improve efficacy. The signals or input could include, for example, any number of the following: sensors on-board the device or connected in the digital ecosystem; evaluation of autonomic function, reflex loop integrity, or excitability using heart rate variability, measuring muscle sympathetic nerve activity (MSNA), and/or measuring h-reflex by sending a stimulation signal and measure response with EMG. In some embodiments, the signals or input can also include sleep sensor sets, including but not limited to accelerometers, gyroscopes, infrared based motion sensors, and/or pressure sensors under a mattress, to measure night time motion as a measure of nocturia events. For example, patients may wear a stimulator while sleeping and therapy can be triggered by night time restlessness, which is an indicator of an upcoming nocturia event. A motion sensor set (e.g., accelerometer, IR based motion sensor, etc.) can measure rapid back and forth movement of legs typically seen when someone has a sense of urgency. An EEG headband could be used to measure different sleep states. Patient and/or physician input can provide feedback on the effectiveness of and/or satisfaction with the therapy into the device or into another connected device. Also, usage of the stimulation device can be tracked; and specific stimulation programs (e.g., a specified set of stimulation parameters) can be changed based on symptoms presented by the patient or outcomes of the therapy.
In some embodiments, a stimulator can be part of a system with sensors to assess the state of sleep and modulate stimulation based on the wearer's sleep state. Sensors could include motion sensors (e.g., body worn accelerometers and gyroscopes, or wireless motion tracking via video or infrared), temperature sensors to measure body temperature, pressure sensor under the mattress to measure movement, heart rate sensors to measure HRV, other sensors to measure sympathetic and parasympathetic activity, and/or EEG sensors to measure brain activity to assess the wearer's sleep state. For example, if nocturia events occur during slow wave sleep when parasympathetic activity can be elevated, stimulation parameters are modulated to affect parasympathetic activity, and vice-versa for sympathetic activity.
In some embodiments, a first stimulation frequency can be provided for short term benefit, and a second stimulation frequency different (e.g., higher or lower) from the first stimulation frequency can be provided for long-term benefit. For example, 10 Hz stimulation can provide a short term benefit and 20 Hz stimulation can provide a long term benefit in some cases. As one example, 10 Hz stimulation can be provided in an initial period with the therapy (e.g., 3 weeks) for acute therapy, then 20 Hz stimulation can be provided for long term maintenance or condition therapy, or vice versa depending on the desired clinical result. In some embodiments, particular sympathetic and/or parasympathetic nervous system targets and circuits can be specifically targeted to modulate upward or downward sympathetic and/or parasympathetic nervous system activity depending on the patient's underlying autonomic nervous system activity. Utilization of data and/or sensors directly or indirectly measuring sympathetic and/or parasympathetic nervous system activity as disclosed, for example, elsewhere herein can be utilized as closed loop feedback inputs into a hardware and/or software controller to modify stimulation parameters, including on a real-time basis.
In some embodiments, the therapy (e.g., stimulation) can be applied for about, at least about, or no more than about 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, or more a day. In some embodiments, the patient is treated nocturnally, such as during sleep, and/or during waking hours. The treatment can be repeated 1, 2, 3, 4, 5, or more times daily or weekly, every other day, every third day, weekly, or other interval depending on the desired clinical result.
In some embodiments, the responsiveness could be dependent on different times of day. For instance, the patient or physician (or algorithm) could pre-schedule different episodic treatment sessions throughout the day and the device could provide treatment stimulation at those different times of day. In one example, treatments are applied at regular or irregular intervals during the day at a frequency related to the typical amount of voiding. In the treatment of nocturia, stimulation could be timed to periodic intervals during a person's sleep. In some embodiments, stimulation schemes are applied to restore autonomic dysregulation based on natural diurnal patterns of sympathetic or parasympathetic activity. Treatment could also occur at irregular intervals that are human-entered or predicted by machine learning from previous days' voiding incidents. In some embodiments, a first frequency (e.g., 10 Hz or 20 Hz) therapy can be applied in the morning for acute day time relief, and a second different higher or lower frequency (e.g., 20 Hz or 10 Hz) therapy can be provided before bed for longer night time relief.
In some embodiments, the responsiveness could be dependent on activity. For instance in nocturia, a motion sensor such as an accelerometer or gyroscope could sense if a person is stirring, which could indicate a desired potential voiding. During that time, the device could turn on to provide appropriate stimulation. In some embodiments, the device could turn off once voiding is complete.
In some embodiments, the responsiveness of stimulation could be dependent on one, two, or more sensors housed in the device to collect, store, and analyze biological measures about the wearer including, but not limited to, motion (e.g., accelerometers, gyroscopes, magnetometer, bend sensors), ground reaction force or foot pressure (e.g., force sensors or pressure insoles), muscle activity (e.g., EMG), cardiovascular measures (e.g., heart rate, HRV), skin conductance (e.g., skin conductance response, galvanic skin response), respiratory rate, skin temperature, and sleep state (e.g., awake, light sleep, deep sleep, REM). Using standard statistical analysis techniques, such as a logistical regression or a Naïve Bayesian classifier, these biological measures can be analyzed to assess the wearer's activity state, such as sedentary versus active, level of stress and/or bladder fluid volume, and the like, which in turn, can serve as a predictor for increases in urinary urgency.
Sympathetic and parasympathetic activity can be measured through several methods, including microneurography (MSNA), catecholamine tests, heart rate, HRV, or galvanic skin response. HRV can provide a quick and effective approximation of autonomic activity in the body. HRV can be determined by analyzing the time intervals between heartbeats, also known as RR intervals. Heart rate can be accurately captured, for example, through recording devices such as chest straps or finger sensors. The differences between successive RR intervals can provide a picture of one's heart health and autonomic activity. Generally speaking, healthier hearts have more variability between successive RR-intervals. This interbeat data can also be used to denote an individual's sympathetic and parasympathetic activity levels. Through frequency-domain analysis, heartbeat frequencies can be separated into distinct bands. High-frequency signals (˜0.15-0.4 Hz) can almost exclusively reflect parasympathetic activity, and low-frequency signals (˜0.04-0.15 Hz) can represent a mixture of sympathetic and parasympathetic activity. Therefore, taking the ratio of high frequency (HF) to low frequency (LF) signals can yield an approximation of one's sympathetic tone. In some embodiments, HRV can be analyzed, for example, under time-domain, geometric domain methods in addition to frequency domain methods. In some embodiments, increased heart rate variability can signify increased parasympathetic response and/or decreased sympathetic response. Decreased heart rate variability can signify decreased parasympathetic response and/or increased sympathetic response. In some embodiments, a system can sense an increase or decrease in HRV of about or more than about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 75%, 100%, or more over a baseline value (or target desired HRV value) and institute a change in one, two, or more stimulation modality parameters accordingly. In some embodiments, the one, two, or more stimulation modalities can be configured to modulate, such as increase or decrease stimulation to one or more nerves (e.g., peripheral nerves) associated with the sympathetic and/or parasympathetic nervous system, and a response to therapy can be confirmed by sensing an increase or decrease in parasympathetic or sympathetic tone, including but not limited to increase or decrease in HRV, changes in high frequency content of HRV, and changes in the ratio of high frequency and low frequency content of HRV. In some embodiments, balance of parasympathetic and sympathetic activity of the bladder reflex loop can be assessed with frequency analysis of heart rate variability measured with pulsed plethysmography with an LED light source and optical sensor disposed in the device that measures fluctuations in light level due to blood flow that target one of the major blood vessels around the knee, which could include one or more of the following, femoral, popliteal, tibial, posterior tibial, anterior tibial, and/or descending genicular arteries or veins.
In some embodiments, a system or method for non-invasively measuring eye muscle movement and/or the blink reflex can be utilized as a biomarker (e.g., a biological marker that can be used to inform diagnosis of a disease state) of diagnosis of overactive bladder or other conditions, monitoring of the progression or efficacy of therapy of overactive bladder or other conditions, and/or be utilized as feedback parameters regarding closed-loop adjustment of therapy. Not to be limited by theory, the centers involved in the control of micturition, such as the medial and lateral regions of the pontine micturition center are in the reticular formation of pontine tegmentum and in close anatomical proximity to regions that control eye muscle movement and/or for coordinating the blink reflex. Thus, such biomarkers can be used to gauge functions that are either integrated in, or mediated by the pontine structures. For example, an increased blink latency time (such as about or at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or more) compared to reference values can be in some cases associated with overactive bladder symptoms. In some embodiments, a patient's baseline eye muscle movement parameter such as blink time can be compared with parameters/times of the patient while on or after therapy for comparison. Some embodiments could involve, for example: video eye tracking or blinking (such as via a camera, including a web camera, tablet or smartphone camera, or a wearable device that includes a camera, e.g., headwear such as a cap, glasses such as a modified Google Glass, and the like); electro-oculography eye muscle recording based on the dipole of the eye; EMG of muscles on the head that control blinking, such as the orbicularis oculi and levator palpebrae superioris muscle; a system to induce a blink, such as a bright light or puff of air into the eye, and then measuring time to blink using a camera or EMG; and/or measurement of the blink reflex with an active stimulation signal, such as applied transcutaneously to the supraorbital nerve and recording of nerve activity of the orbicularis oculi.
In some embodiments, any form of stimulation as disclosed herein can be utilized to apply stimulation to one, two, or more acupuncture points. In some embodiments, the acupuncture points to be stimulated could include any one, two, three, four, five, six, seven, eight, nine, ten, or any other number of the following: BL18 (Ganshu), BL23 (Shenshu), BL27 (Xiaochangshu); BL28 (Pangguangshu); BL32 (Ciliao); BL33 (Zhongliao); BL53 (Baohuang); CV2 (Qugu); CV3 (Zhongji); CV4 (Guanyuan); CV5 (Shinen); CV6 (Qihai); GB34 (Yanglingquan); KI7 (Fuliu); KI10 (Yingu); LR1 (Dadun); LR2 (Xingjian); LR8 (Quan); N-BW-38 (Xiajiaoshu); SP6 (Sanyinjiao); SP9 (Yinlingquan); and/or ST28 (Shuidao). In some embodiments, the points to be stimulated include BL18, BL23, BL28, and CV2. In some embodiments, the points to be stimulated include ST28, SP6, BL23, BL28, BL32, BL33, BL53, CV3, and N-BW-38. In some embodiments, the points to be stimulated include SP6, BL23, BL27, BL28, BL33, and CV4. In some embodiments, the points to be stimulated include SP9, LR1, LR2, CV4, and CV6. In some embodiments, the points to be stimulated include SP6, SP9, BL23, CV3, and CV6. In some embodiments, the points to be stimulated include SP9 and GB34. In some embodiments, the points to be stimulated include SP9, KI7, KI10, and LR8. In some embodiments, the point to be stimulated is either CV5 alone or BL39 alone, or a combination thereof. Other permutations of stimulation points are also possible, depending on the desired clinical result.
A large source of error in optical measurements of heart rate is motion artifacts due to relative motion between the optical sensor and the blood vessel being measures. In some embodiments, the optical heart rate sensor has an adhesive on the side of housing that contacts the wearer's skin to reduce relative motion between the sensor and the target blood vessel.
In some embodiments, one, two, or more additional sensors are disposed in the device, including electrical sensors in contact with the wearer's skin to measure cardiac activity or pressure sensors to measure changes in blood vessels, to be used in combination with an optical sensor to improve the fidelity of heart rate measurement.
In some embodiments, the system and device have memory and a processor to extract RR intervals from sensor data, calculate variability of RR intervals, transform data into frequency domain, and calculate high frequency signals, low frequency signals, and the ration of the high frequency and low frequency signals.
In some embodiments, the heart rate sensor can store collected data for specified time period to gather adequate date for heart rate variability calculation. Specified time period can range in some cases from 1-60 seconds, and may extend to 10 minutes or more.
In some embodiments, electrodermal activity, also known as galvanic skin response or skin conductance response, for example, can be measured using sensors, such as electrodes. Galvanic skin response is the change of the electrical resistance of the skin caused by emotional stress, and measurable with, e.g., a sensitive galvanometer. Not to be limited by theory, skin resistance varies with the state of sweat glands in the skin. Sweating is controlled by the sympathetic nervous system, and skin conductance can be an indication of psychological or physiological arousal. If the sympathetic nervous system is highly aroused, then sweat gland activity also increases, which in turn increases skin conductance. In this way, skin conductance can be a measure of emotional and sympathetic responses, which can be measured, and the feedback data can be sent to the controller, which will in turn modulate stimulation to, for example, decrease sympathetic nervous system activity. Other non-limiting parameters associated with sympathetic and/or parasympathetic nervous system activity that can be sensed include, for example, sweating during particular times of the day and/or night, sleep states as detected, for example, by an EEG headband (to determine when sympathetic and/or parasympathetic activity is particularly high or low, and potentially correlating a sleep state such as stage 1, 2, 3, 4, or REM with nocturia), and/or motion. In some embodiments, a diagnostic and/or combination diagnostic/stimulation device can be configured to measure a person's heart rate and galvanic skin response for improved estimation of the person's autonomic activity. In some embodiments, a wearable device, such as a wrist-worn device can include both electrodermal activity (EDA) sensors and optical heart rate sensors. This combination of data can in some embodiments advantageously and synergistically provide improved estimation of sympathetic and parasympathetic activity than a single measure alone. In some embodiments, the system can include multiple sensors to measure electrodemal activity in conjunction with heart rate and HRV. Data from the multiple sensors can be analyzed by a hardware or software processor and combined to provide a more accurate estimation of sympathetic and/or parasympathetic activity. In some embodiments, the EDA and HR sensors can be disposed in a wrist-worn device that communicates via a wired or wireless connection to the stimulator or to send data to a centralized remote server (e.g., the cloud). Stimulation parameters, nerve target locations (e.g., tibial and/or saphenous nerves for example) or dosing regimen (e.g., duration or frequency of stimulation sessions) could be adjusted based on estimations of sympathetic and/or parasympathetic activity. Adjustments could be made in real-time, or in subsequent stimulation sessions. In some embodiments, stimulation frequency can be adjusted to either increase or decrease autonomic activity modulated by a single specific nerve, or multiple nerves. For example, in some embodiments, relatively low frequency stimulation of a target nerve (e.g., below a threshold value, e.g., about 5 Hz) can potentially inhibit the nerve and thus decreases sympathetic activity, while higher frequency stimulation (e.g., above a threshold value, e.g., about 5 Hz) can potentially excite the nerve and thus increases sympathetic activity. The same effect can occur with the same or other target nerves to regulate parasympathetic activity. In other words, in some embodiments, relatively low frequency stimulation of the target nerve (e.g., below a threshold value, e.g., about 5 Hz) can potentially inhibit the nerve and thus decreases parasympathetic activity, while higher frequency stimulation (e.g., above a threshold value, e.g., about 5 Hz) can potentially excite the nerve and thus increases parasympathetic activity. Not to be limited by theory, depending on the stimulation parameters for example, in some cases stimulating the target nerve can increase or decrease either sympathetic activity, parasympathetic activity, or both. In some embodiments, stimulation of the saphenous nerve can affect sympathetic activity, and stimulation of the tibial nerve can affect parasympathetic activity.
The device could also be responsive to number of episodes of symptoms, including overactive bladder. If more episodes occur in one day, treatment can be increased by increasing the amplitude of the stimulation, duration of the stimulation, or number of treatment sessions, for example.
The number of episodes of symptoms such as overactive bladder could be detected in various ways to control the stimulation applied by system and devices. In some embodiments, the patient can enter events related to symptoms of overactive bladder, including but not limited to bladder voiding events, urgency event, or incontinence events on a mobile device. In some embodiments, location services on the device, such as GPS, can detect when the person has entered a building or bathroom.
Information regarding bladder voiding can be combined in some embodiments with an understanding of the amount of fluid a person has consumed in order to better apply a desired amount of treatment. For example, in days where more beverages were consumed by an individual, more bladder voiding would be expected.
One method of recording the times and types of beverages consumed is through a journal or diary, for example on a smartphone, tablet, or other device. Another method of achieving this is to use a device such as a smart cup that identifies the types and amounts of beverages consumed through the day and syncs this information to the system or device. This information can advantageously be an automatic journal of the amount of liquids consumed through the day.
Bladder control and comfort require a delicate balance of sympathetic, parasympathetic, somatic efferent and afferent innervation of the bladder reflex circuits. In some embodiments, a variable frequency stimulator in electrical connection with three or more electrodes to target at least two nerves that provide sympathetic, parasympathetic and somatic input into the bladder reflex circuits. In some embodiments, the device is disposed in a knee strap fitted just below the knee with a fastening mechanism to hold the device securely on the body. In some embodiments, the electrodes, constructed from an adhesive hydrogel, are disposed in the housing of the device allowing the device to adhere to the wearer's skin. In some embodiments, a system can include a plurality of stimulators that communicate with each other wirelessly and provided a synchronized continuous or patterned stimulation. In some embodiments, multiple stimulators may be in electrical connection with multiple electrode pairs to stimulate multiple nerves simultaneously. Each stimulator in the system can communicate with each other via a wired or wireless connection. Multiple stimulators can provide synchronized stimulation to the multiple nerves. Stimulation may be, for example, burst, offset, or alternating between the multiple nerves.
In some embodiments, systems and methods can stimulate a plurality of nerves associated with bladder function, including but not limited to peripheral nerves in different anatomical locations. For example, stimulation could include one or more nerve targets on an extremity or extremities of a patient, and one or more nerve targets on the head of a patient. Some embodiments can involve stimulation of saphenous, tibial nerves, and/or other nerves as disclosed elsewhere herein in coordination with pontine nuclei stimulation via peripheral nerve targets in order to control centers involved in micturition. The stimulation of the saphenous, tibial, and/or other nerves could be simultaneous, overlapping, or at different times with respect to that of the stimulation of the pontine micturition center, such as at intervals disclosed elsewhere herein. The centers involved in the control of micturition, e.g., the medial and lateral regions of the pontine micturition center are in the reticular formation of pontine tegmentum which lies in close anatomical proximity to regions innervated by the trigeminal and facial nerve.
In some embodiments, as shown schematically in
In some embodiments, the weave of the brace or sock could be designed to provide tight pressure at the knee, calf, ankle, or other desired region of the device, similar to the weave of commonly found anklet socks. Electrodes can also be made from, for example, conventional hydrogels. In some cases, a clasp or fastening element such as Velcro may be needed because with sticky electrodes, the device cannot be easily slid on the foot. In some embodiments, the, e.g., knee, calf, ankle brace or anklet embodiments can be extended to electrode positions that are on the top (dorsal) or bottom (ventral) surfaces of the foot. In some cases, a sock with electrodes on the sole of the foot can be used with connectivity through the sock to an electronics module located near the ankle.
In some embodiments if the electrodes 606 are sticky, as shown in the embodiment of
In another embodiment, as illustrated in
Several peripheral nerves in addition to, or instead of the tibial nerve can serve as targets for urinary neuromodulation, including the pudendal and dorsal genital nerve, with acute and/or chronic effects on bladder function in animal and human experimental studies. Saphenous nerve stimulation can acutely or chronically reduce bladder hyperexcitability. The saphenous nerve is a purely sensory nerve that innervates the skin on the medial lower leg. Its proximity to the skin surface makes it an advantageous target in some embodiments for transcutaneous stimulation. Selective stimulation of the saphenous nerve can in some embodiments advantageously reduce overactive bladder symptoms. In some embodiments, peripheral nerves can be independently targeted with specific same or differing frequencies to prove acute or chronic relief of symptoms of overactive bladder, and/or to alter sympathetic and/or parasympathetic activity.
The effects of peripheral nerve stimulation on bladder function may occur only during the period of active stimulation in some embodiments, or may outlast the stimulation period after stimulation has ceased. Different mechanisms such as the modulation of urinary reflexes or induction of brain and/or spinal plasticity can be triggered using systems and methods as disclosed herein. Furthermore, in some cases the onset of the effects of stimulation may occur acutely or only after several stimulation sessions in a chronic manner. For example, the effect of transcutaneous or percutaneous tibial nerve stimulation on patient related outcomes is estimated in some embodiments at 4-6 weeks after the initiation of weekly stimulation sessions. Depending on the underlying mechanisms and the time course of beneficial effects, stimulation may require delivery in a continuous fashion such as in sacral nerve stimulation, in discrete scheduled sessions or in an on-demand, conditional manner. Conditional stimulation may either rely on patient control to identify the sense of urinary urge or automated detection of an involuntary detrusor contraction (IDC) which is responsible for urgency symptoms or evolution to frank incontinence.
Conditional stimulation of the dorsal genital nerve and/or pudendal nerve can be advantageous in some embodiments. Alternatively or in addition, continuous stimulation can be utilized to control bladder symptoms. The advantages of conditional stimulation in some embodiments can include customization of symptom control, improved battery life, and reduction of the risk of habituation with continuous stimulation. A patient controlled conditional stimulation device for overactive bladder may be effective for suppressing urge symptoms prior to the progression to incontinence.
The stimulation frequency can be varied depending on the desired clinical result. In some embodiments, a relatively higher frequency, such as between about 10 Hz and about 33 Hz, between about 10 Hz and about 30 Hz, between about 10 Hz and about 20 Hz, or between about 20 Hz and about 33 Hz, or about or at least about 10 Hz, 15 Hz, 20 Hz, 25 Hz, 30 Hz, 33 Hz, 35 Hz, or more can be used. The stimulation frequency can also be tailored to the specific nerve targeted. In some embodiments, lower stimulation rates such as 2 Hz can have an excitatory effect on bladder function and worsen incontinence. However, in some embodiments, a frequency of about or no more than about 10 Hz, 9 Hz, 8 Hz, 7 Hz, 6 Hz, 5 Hz, 4 Hz, 3 Hz, 2 Hz, or 1 Hz can be utilized. In some embodiments, the stimulation frequency could be in the kHz range, such as, for example, between about 1 kHz and about 100 kHz, such as between about 10 kHz and about 50 kHz. The stimulation could be regular, irregular, or random in some embodiments. In some embodiments, a frequency or a plurality of frequencies for one, two, or more nerves could be selected from, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 Hz. In some embodiments, two or more of the same or different frequencies or frequency ranges can be applied to the same or different target nerves.
The exact location of stimulation in the lower leg can vary depending on the desired target. For example, the tibial nerve may be stimulated at the level of the ankle or behind the knee. As the saphenous nerve territory is over the medial lower leg, stimulation of the nerve may be achieved at the ankle or closer to the knee in some cases.
In some embodiments, stimulation of the saphenous nerve can be used instead of or in conjunction with tibial nerve stimulation to treat overactive bladder and/or urinary incontinence. The saphenous nerve runs through the upper leg, descends along the medial side of the knee, descends along the tibial side of the lower leg and divides into two branches, a branch that continues to descend along the tibia that extends to the ankle and a branch that passes in front of the ankle and extends along the medial side of the foot.
In some embodiments, a stimulator worn around the ankle or lower leg or knee or upper leg can be used to stimulate the saphenous nerve and, optionally, also the tibial nerve. In other embodiments, the stimulator can be worn around any other part of the leg or foot in order to stimulate the saphenous nerve at other locations. The electrode(s) of the stimulator can be placed proximate or over the saphenous nerve.
In some embodiments, the stimulation can be electrical and be provided transcutaneously using an electrode placed on the patient's skin. In some embodiments, the stimulation of the saphenous nerve can be patient activated. In some embodiments, the stimulation of the saphenous nerve can be automated and/or patient activated. In some embodiments, the stimulation of the saphenous nerve can be solely patient activated, meaning the stimulation is only provided while the patient is awake. If stimulation while the patient is asleep is desired, an automated stimulation regimen can be provided.
In some embodiments, a device for stimulating one, two, or more nerves is illustrated schematically in
In some embodiments, as illustrated in
In some embodiments, an implanted electrode that stimulates the nerve can be powered by an external stimulation unit, and the stimulation pulse is directly coupled to the electrode and nerve using capacitive or inductive coupling. In some embodiments, the wearable device can communicate with an external computer or device (e.g., tablet, smartphone, smartwatch, or custom base station) to store data. Communication between the wearable device and external device can be a direct, physical connection, or with a wireless communication connection such as Bluetooth, Wi-Fi, Zigbee, GSM, or cellular for example. In some embodiments, the system communicates with an external, portable computational device, such as a smartphone via an app, or other mobile digital interaction. The device may be used to track information of relevant events either user-entered or automatically captured from biological sensors, such as the time since the last urination and fluid intake, or biometric data predicting upcoming episodes of urinary incontinence or urinary urgency. This information may be used to close the loop to adjust stimulation parameters (waveforms, amplitude, on/off) or suggest user behaviors.
In some embodiments, the wearable device can have a GPS or similar device to track the location and assess activity of the wearer. GPS measures can be combined with mapping or location systems to determine context of the wearer's activity (e.g., gym versus office) or determine changes in elevation during specific activities, such as running or cycling.
In some embodiments, the wearable device can track parameters about stimulation provided by the stimulation unit, including time of stimulation, duration of the stimulation session, and power used by the stimulation unit. This data can be stored on memory in the wearable device, processed by the wearable device, and/or transmitted to an external computing device.
The stimulation unit can use switches or electrical sensor to detect connection of electrodes: (1) to ensure proper and unique electrodes are being installed (e.g., not using a different or incorrect type of electrode) communicating a unique code, for example via RFID, (2) to regulate the number of uses for each electrode to prevent over use, and/or (3) to prevent the usage of the device without an electrode to prevent small shock.
In some embodiments, a system may include features to increase skin comfort. One solution is to use a high frequency carrier (e.g., kHz such as 1 kHz or greater) wave over the low frequency beats (10 to 200 Hz), or to position electrodes such that the interaction of two waveforms combines to produce a low frequency beat.
In some embodiments, systems and methods of peripheral nerve stimulation can be provided that target one, two, or more individual nerves as illustrated in
In some embodiments, disclosed herein is a dual nerve stimulator with the entire device or a portion thereof configured to be positioned just below the knee to target the saphenous and tibial nerves, including sensors for measuring slow changes in heart rate variability to assess autonomic dysregulation (e.g., to balance sympathetic and parasympathetic activity), and/or accelerometry for measuring overall activity, where the nerve targeted and the frequency of stimulation are controlled based on sensor data. Stimulation of each of the target nerves can be turned on or off independently, and the stimulation frequency can be adjusted independently to provide acute or chronic relief of symptoms due to a condition such as overactive bladder, as needed.
In some embodiments, the treatment device 10 can be a wearable device including an electronics box or housing 12 containing the stimulator or pulse generator 18, sensors 20, and other associated electronics such as a controller or processor 22 for executing instructions, memory 24 for storing instructions, a user interface 26 which can include a display and buttons, a communications module 28, a battery 30 that can be rechargeable, and optionally an inductive coil 32 for charging the battery 30, and the like. The device 10 can also include, for example, a band or sleeve to hold all the components together and securely fasten the device around the leg, knee, foot, or ankle of an individual. The device can also include, for example, a pair of electrodes on the band or sleeve.
Additional system and device embodiments are shown in
In some embodiments, stimulating three or more electrodes can be used to stimulate two or more nerves. In some embodiments as shown in
There are many transistor circuits or components like polyfuses to limit or shutdown the current to a particular node. These circuits and its components, such as the stimulator, switches, and current limiters, can be controlled and/or be programmable by a microprocessor 1216 in real-time. The 15 switch matrix allows multiple electrodes to be connected to the same stimulator contacts at a given time for maximum flexibility. In addition, electrodes can be switched between the positive and negative contacts of the stimulator to produce a bipolar pulse.
In some embodiments, disclosed herein are systems and methods for stimulating a plurality of nerves for the treatment of conditions including but not limited to overactive bladder. Stimulation of 2, 3, or more nerves, such as the saphenous and tibial nerve could be used for the treatment of conditions such as overactive bladder. Dual nerve stimulation can in some cases synergistically increase the effectiveness of therapy by combining synergistically the effects of, for example, saphenous and tibial nerve stimulation. In some embodiments, including those disclosed in connection with
In some embodiments, as illustrated schematically in
Another possible configuration shown in
A 4 week proof of concept (POC) study of transcutaneous saphenous nerve stimulation was performed, and 7 subjects were enrolled. Eligibility was confirmed using industry-standard OAB-V8 screen and a week of baseline data. The subjects were treated with 60 minutes of daily saphenous nerve stimulation. Data collected included a weekly 3-day voiding diary, and ICIQ-SF and OAB-Q patient assessments at a 4 week appointment. The study data is shown in
A 4 week proof of concept (POC) study of transcutaneous tibial nerve stimulation was performed, and 4 subjects were enrolled. Eligibility was confirmed using industry-standard OAB-V8 screen and a week of baseline data. The subjects were treated with 60 minutes of daily tibial nerve stimulation. Data collected included frequency, incontinence, and nocturia data. The study data is shown in
As noted above, HRV can have a direct relationship with sympathetic and parasympathetic activity. Not to be limited by theory, sympathetic and parasympathetic activity can be abnormal in subjects with overactive bladder, which is a dysregulation of the bladder reflex loop controlled by the autonomic nervous system. In subjects with OAB, the parasympathetic nerves (e.g., pelvic nerves) can cause the detrusor to contract due to elevated activity after voiding. This parasympathetic overactivity can cause the bladder to contract again before it is full. In subjects with OAB, sympathetic activity can be elevated when the bladder is full, leading to sensory urgency. Sympathetic overactivity can be associated with OAB without detrusor muscle overactivity, and parasympathetic overactivity can be associated with OAB with detrusor muscle overactivity.
HRV measurements in subjects with OAB can be significantly different during bladder filling and voiding compared to controls. Through frequency-domain analysis, heartbeat frequencies can be separated into distinct bands. High-frequency signals (between about 0.15 Hz and about 0.4 Hz) can almost exclusively reflect parasympathetic activity, and low-frequency signals (between about 0.04 Hz and about 0.15 Hz) can represent a mixture of sympathetic and parasympathetic activity. In some embodiments, taking the ratio of high frequency (HF) to low frequency (LF) signals yields an approximation of one's sympathetic tone. Very low frequency (VLF) signals (between about 0.004 Hz and about 0.040 Hz) can also be evaluated to assess parasympathetic activity. The total power of HRV in the frequency domain can also be evaluated to assess autonomic activity.
Sympathetic and parasympathetic functions can also be evaluated, for example, by analyzing mean normal-to-normal intervals, e.g., all intervals between adjacent QRS complexes of measured cardiac rhythm, including the number of interval differences of successive NN intervals greater than 50 milliseconds; square root of the mean squared differences of successive NN intervals, and standard deviation of the NN intervals.
In some embodiments, sympathetic activity can also be assessed using more traditional techniques, such as measuring blood pressure changes before release and before starting a hand grip exercise, or measuring blood pressure changes before and after immersing the hand in a bath of cold water (e.g., cold pressor test). Parasympathetic activity can be assessed by measuring heart rate response during deep breathing, or heart rate response to standing from lying or seated position (orthostatics). Both sympathetic and parasympathetic activity can be assessed during the Valsalva maneuver (e.g., blowing into a mercury manometer and maintaining a pressure of about or at least about 40 mmHg), or orthostatic heart rate response (e.g., to standing from lying or seated position).
Additional specific examples of methodologies that can treat a disorder relating to bladder dysfunction by restoring balance to sympathetic and parasympathetic nervous system activity, including but not limited to reducing sympathetic and/or parasympathetic nervous system activation relating to neural bladder circuits, are disclosed herein.
In some embodiments, sympathetic and parasympathetic activity are assessed prior to initial stimulation to select specific nerve targets, stimulation waveforms, stimulator parameters, or dosing of stimulation (e.g., time of day, duration of stimulation, number of times per day or week). In other embodiments, a default stimulation is applied in a trial fashion, and only if a person does not respond to treatment is sympathetic and parasympathetic activity assessed, as illustrated in
In some embodiments, if a person does not respond to therapy, a number of parameters can be altered to modify therapy, including but not limited to increasing or decreasing, or otherwise changing any number of the following: duration of session (e.g., 20-120 minutes); number of sessions per day or week (e.g., 2 times per day to 3 times per week); time of day or night of stimulation; stimulation frequency; bursting or other stimulation pattern (including bursting frequency); nerve target (e.g., saphenous or tibial); and/or stimulation amplitude.
In some embodiments, disclosed herein are wearable systems and methods that can utilize transcutaneous sensory stimulation in the form of a burst pattern, e.g., a theta burst pattern to improve the symptoms of overactive bladder and a variety of other conditions, including but not limited to those disclosed herein. Noninvasive peripheral nerve theta burst stimulation may be effective in driving cortical or spinal plasticity to reduce symptoms and improve an individual's quality of life.
In some embodiments, the stimulation involves patterns of electromagnetic stimulation of peripheral nerves. The patterned stimulation could be a bursting stimulation, such as an on/off pattern that repeats at regular intervals (e.g., on for 10 ms, off for 20 ms, etc.), or non-burst patterned stimulation that can be more complex in some embodiments, such as a stochastic pattern or a sinusoidal envelope for example. The electromagnetic stimulation could include, for example, electrical energy, mechanical energy (e.g., vibration), magnetic energy, ultrasound energy, radiofrequency energy, thermal energy, light energy (such as infrared or ultraviolet energy for example), and/or microwave energy, or combinations thereof. In some embodiments, the stimulation is limited to only electrical energy (e.g., no magnetic or other types of energy are applied). The peripheral stimulation could include transcutaneous, percutaneous, and/or implanted stimulation.
In some embodiments, the stimulation involves non-invasive transcutaneous electrical patterned or burst stimulation of peripheral nerves, including afferent and/or efferent nerves. Not to be limited by theory, but burst stimulation of peripheral nerves can unexpectedly result in one or more of the following compared with conventional or continuous stimulation: greater efficacy; greater plasticity; increased tolerance or tolerability; reduced effects of habituation; increased comfort; and/or reduced treatment time required to achieve the same beneficial effects. Burst stimulation of peripheral nerves, including afferent nerves, can in some cases deliver a more efficacious therapy by remotely accelerating plasticity of one or more central nervous system (e.g., brain and/or spinal cord) circuits, in other words creating plasticity in neural circuits for a period of time that is far longer than the duration of the stimulation session, such as, for example, about or at least about 6 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 12 months, 18 months, 24 months, 36 months, or even longer. Peripheral stimulation in some cases can be more convenient and comfortable for the user than central stimulation (e.g., transcranial stimulation and/or spinal stimulation) and can be more suitable for home and ambulatory use.
In some embodiments, the burst stimulation includes theta burst stimulation. Theta burst stimulation (TBS) is a patterned form of repetitive stimulation that uses high frequency pulses separated by varying inter-burst intervals. Originally used for the induction of long term potentiation in hippocampal learning and memory research, theta burst stimulation in the form of repetitive magnetic stimulation (rTMS) has been demonstrated to noninvasively induce plasticity in humans in the motor, sensory and visual cortex. Depending on various parameters including the duration and continuity of stimulation, a long term potentiation or depression (LTP/LTD) like effect can be observed which are surrogate measures of synaptic efficacy. The number of sessions and the spacing interval between individual sessions of stimulation can also have an effect on the duration of the induced response. The level of muscle relaxation before or during stimulation can also affect the resulting direction or amplitude of plasticity induction suggesting that homeostatic mechanisms are in place that adjust the threshold for plasticity depending on prior synaptic activity. The effective modulation of nervous system plasticity demonstrated with theta burst stimulation can have great potential for the treatment of various neurologic disorders, and can have an effect on other central neural circuits.
In some embodiments, theta burst stimulation can take the form of intermittent theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS), and intermediate theta burst stimulation (imTBS). Non-limiting examples of iTBS, cTBS, and imTBS are illustrated in
In some embodiments, each burst can include a plurality of stimuli, such as about or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more stimuli. Each burst can have the same, or a variable number of stimuli.
In some embodiments, the intraburst frequency could be about or at least about 10 Hz, 20 Hz, 30 Hz, 40 Hz, 50 Hz, 100 Hz, 250 Hz, 500 Hz, 1 kHz, or more. In some embodiments, intraburst frequency could vary between about 10 Hz and about 20 kHz. Intraburst frequency can also be varied in a random or pseudorandom fashion during the burst to reduce habituation and/or increase comfort. In other embodiments, the intraburst frequency can be between about 10 Hz and about 250 Hz, between about 50 Hz and about 150 Hz, between about 10 Hz and about 100 Hz, between about 100 Hz and about 150 Hz, between about 50 Hz and about 250 Hz, or between about 50 Hz to about 1000 Hz, in order to maximize tremor reduction, improve comfort, reduce habituation, and/or reduce power consumption of the electrical stimulator device.
In some embodiments, the interburst frequency can be between about 1 Hz to about 20 Hz, such as between about 4 Hz (250 ms between the start of each burst) and about 12 Hz (83 ms), such as between about 4 Hz (250 ms) and about 8 Hz (142 ms) which is generally accepted as the theta band frequency, including about 5 Hz (200 ms), or in some embodiments between about 3.5 Hz and about 7.5 Hz, or between about 6 Hz and about 10 Hz.
In some embodiments, the inter-session frequency can be between about 1 minute and about 12 hours, such as between about 5 minutes and about 120 minutes, between about 5 minutes and about 60 minutes, between about 10 minutes and about 30 minutes, about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, or 720 minutes, or ranges incorporating any two of the aforementioned values.
In some embodiments, a repetitive patterned stimulation known as quadripulse stimulation could be used, which includes four pulses at a short interval frequency (interstimulus interval of 1.5 ms) repeated at about 0.2 Hz for a period of time, such as about 30 minutes. Quadripulse stimulation has been shown to induce prolonged plasticity. Variation of the intraburst frequency using this paradigm can influence the direction of induced plasticity. These repetitive small pulses could be anywhere between 2-10 pulses or more.
Other burst patterns other than theta burst stimulation can also be used, instead or in addition. Some non-limiting examples include delta (0-4 Hz), alpha (8-12 Hz), beta (12-30 Hz), and gamma (30-100 Hz) inter-burst frequencies. In some embodiments, peripheral burst stimulation can include a sinusoidal, square, rectangular, triangular, sawtooth, or other waveform.
In some embodiments, burst transcutaneous peripheral electrical stimulation can be preferred in some cases over burst transcutaneous peripheral magnetic stimulation. In some cases transcutaneous peripheral electrical stimulation can be advantageous because magnetic theta burst can require more power and/or be a heavier device. Electrical stimulation can advantageously provide ambulatory home use, and a more precise stimulation of targeted nerves by controlling flow of current between electrodes or by using a percutaneous needle. In some embodiments, stimulation can be provided at a fixed bursting frequency without measuring for/adjusting for a measured frequency of a physiologic or pathologic parameter or symptom associated with a subject.
In one embodiment, the timing of individual sessions of stimulation can be varied in order to prolong the duration of plasticity, as illustrated in
The effects of an individual stimulation session may be modulated by a priming stimulation session, an example of which is illustrated in
In some embodiments, disclosed herein are devices for burst peripheral stimulation of one, two, or more nerves according to some embodiments of the invention. The devices can include a housing and one, two or more effectors, power sources, and/or controls. In some embodiments, the device further includes one or more sensors. The effectors can include a pulse generator and electrodes for delivering electrical stimulation, and/or can be a mechanical stimulator for delivering mechanical stimulation, such as vibratory stimulation, for example. The stimulation can be, for example, burst/patterned electrical stimulation as disclosed elsewhere herein. The sensors can include, for example, accelerometers, gyroscopes, and electrodes to measure electrical activity including nerve activity and muscle activity.
In some embodiments, electrical peripheral nerve burst stimulation can be utilized to stimulate one, two, or more nerves associated with bladder function, and unexpectedly effectively create plasticity in bladder neural circuits. In some embodiments, the peripheral nerve could be one or more of the saphenous nerve and/or the tibial nerves, for example. Such systems and methods can be combined with, or modified for use with systems and methods in PCT App. No. PCT/US2017/014431 filed on Jan. 20, 2017, which is hereby incorporated by reference in its entirety.
In some embodiments, disclosed is a method of treating urinary symptoms in a patient with transcutaneous stimulation of a nerve, such as the saphenous nerve or the tibial nerve. The method can include positioning a first peripheral nerve effector on the patient's skin to stimulate the saphenous nerve of the patient, delivering a first burst (e.g., theta burst) electrical nerve stimulation signal transcutaneously to the saphenous nerve through the first peripheral nerve effector, and receiving an input relating to autonomic nervous system activity of the patient to create a plastic effect and modulate a neural network associated with the bladder. The input can be used to modify the stimulation waveform or other parameters, such as the location, timing, frequency, amplitude, and the like as disclosed elsewhere herein. In some embodiments, the method does not utilize any implantable components, and only involves transcutaneous stimulation.
In some embodiments, disclosed herein is a method involving dual transcutaneous electrical burst stimulation of a saphenous nerve and a tibial nerve. The method can include positioning a first peripheral nerve effector on the patient's skin to stimulate the saphenous nerve of the patient; positioning a second peripheral nerve effector on the patient's skin to stimulate the tibial nerve of the patient; delivering a first burst electrical nerve stimulation signal transcutaneously to the saphenous nerve through the first peripheral nerve effector; delivering a second burst electrical nerve stimulation signal transcutaneously to the tibial nerve through the second peripheral nerve effector; receiving an input relating to autonomic nervous system activity of the patient; and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function with plasticity based on the input to balance parasympathetic and sympathetic nervous system activity of the patient. In some embodiments, patterned, such as burst stimulation, can be applied to one, two, or more nerves. Not to be limited by theory, each discrete nerve can modulate a different aspect of a physiologic reflex loop (e.g., the tibial nerve can modulate the parasympathetic reflex loop, and the saphenous nerve can modulate the sympathetic reflex loop).
In some embodiments, the weave of the brace or sock could be designed to provide tight pressure at the knee, calf, ankle, or other desired region of the device, similar to the weave of commonly found anklet socks. Electrodes can also be made from, for example, conventional hydrogels. In some cases, a clasp or fastening element such as Velcro may be needed because with sticky electrodes, the device cannot be easily slid on the foot. In some embodiments, the, e.g., knee, calf, ankle brace or anklet embodiments can be extended to electrode positions that are on the top (dorsal) or bottom (ventral) surfaces of the foot. In some cases, a sock with electrodes on the sole of the foot can be used with connectivity through the sock to an electronics module located near the ankle.
Combination Therapy
In some embodiments, burst peripheral nerve stimulation can be paired/combined with central nervous system stimulation for unexpectedly synergistic effects. For example, burst peripheral nerve stimulation can be combined with a noninvasive brain stimulation device or an invasive brain stimulation device, and can also include a feedback device, e.g., sensors, and a controller to synchronize stimulation between the peripheral nerve stimulation device and the central nervous system stimulation device.
In another embodiment, the system may include a noninvasive transcranial stimulator using transcranial alternating cranial stimulation (TACS) in the form of a hat, cap, headband having electrodes 1902, for example in combination with a peripheral stimulator 1901 in another location, such as the lower extremity, as illustrated in
In a further embodiment, a transcranial direct current stimulation (tDCS) or transcranial magnetic stimulation (TMS) can be applied to alter the excitability of the brain and modulate the efficacy of plasticity induction. Transcranial direct current stimulation uses weak electrical currents (roughly 1-2 mA) over the scalp and has been shown to affect underlying cortical network excitability. Additionally, electrical or magnetic stimulation of the spinal cord or spinal cord neural circuits can be applied to alter excitability of central neural circuits not in the brain, such as central pattern generators. Other CNS stimulation devices including optical, ultrasound, and the like can also be utilized.
In some embodiments, pulse width of an electrical stimulation waveform can be modified in order to stimulate the nerve fibers that affect that particular region or nucleus of the brain that is affected by or associated with the disease. Amplitude in the peripheral system may also be modified in order to select the right nerve type, according to the proper stimulation duration curves.
In some embodiments, the transcranial stimulator and the peripheral stimulator may communicate with wired or wireless communication in order to synchronize the timing of different stimulations in the central and peripheral systems. In some cases, the TACs may be activated prior to peripheral stimulation in order to synchronize the oscillation, for instance. Then the peripheral theta burst stimulation, in combination with the TACs, would altering the neural circuit dynamics associated with overactive bladder or another disorder.
In another embodiment, a theta burst stimulation pattern could be applied with an nerve stimulation implant to deeper nerves, such as the sacral or pudendal nerve, in order to improve symptoms associated with overactive bladder, stress urinary incontinence, lower urinary tract symptoms, or other bladder diseases.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “stimulating a peripheral nerve” includes “instructing the stimulating of a peripheral nerve.” Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
This application claims the benefit as a continuation of U.S. patent application Ser. No. 16/500,377 filed on Oct. 2, 2019, which is the U.S. National Stage under 37 C.F.R. § 371 of PCT App. No. PCT/US2018/025752 filed on Apr. 2, 2018, which in turn claims the benefit under 35 U.S.C. 119(e) as a nonprovisional application of U.S. Prov. App. No. 62/481,006 filed on Apr. 3, 2017 and U.S. Prov. App. Nos. 62/534,074 filed on Jul. 18, 2017, both of which are incorporated by reference in their entireties. This application is also related to PCT App. No. PCT/US2017/014431 filed on Jan. 20, 2017, which is a nonprovisional application that claims the benefit under 35 U.S.C. § 119(e) of U.S. Prov. App. No. 62/281,606 filed on Jan. 21, 2016, U.S. Prov. App. No. 62/352,462 filed on Jun. 20, 2016, and U.S. Prov. App. No. 62/365,326 filed on Jul. 21, 2016, each of which are hereby incorporated by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3204637 | Frank et al. | Sep 1965 | A |
| 3870051 | Brindley | Mar 1975 | A |
| 4103808 | Hallman et al. | Aug 1978 | A |
| 4300575 | Wilson | Nov 1981 | A |
| 4458696 | Larimore | Jul 1984 | A |
| 4461075 | Bailey | Jul 1984 | A |
| 4539996 | Engel | Sep 1985 | A |
| 4569351 | Tang | Feb 1986 | A |
| 4582049 | Ylvisaker | Apr 1986 | A |
| 4729377 | Granek et al. | Mar 1988 | A |
| 4739764 | Lue et al. | Apr 1988 | A |
| 4763659 | Dunseath, Jr. | Aug 1988 | A |
| 4771779 | Tanagho et al. | Sep 1988 | A |
| 4981146 | Bertolucci | Jan 1991 | A |
| 4982432 | Clark et al. | Jan 1991 | A |
| 4996987 | Petrofsky | Mar 1991 | A |
| 5003978 | Dunseath, Jr. | Apr 1991 | A |
| 5052391 | Silverstone et al. | Oct 1991 | A |
| 5070862 | Berlant | Dec 1991 | A |
| 5137507 | Park | Aug 1992 | A |
| 5330516 | Nathan | Jul 1994 | A |
| 5397338 | Grey et al. | Mar 1995 | A |
| 5514175 | Kim et al. | May 1996 | A |
| 5540235 | Wilson | Jul 1996 | A |
| 5562707 | Prochazka et al. | Oct 1996 | A |
| 5562717 | Tippey et al. | Oct 1996 | A |
| 5573011 | Felsing | Nov 1996 | A |
| 5575294 | Perry et al. | Nov 1996 | A |
| 5606968 | Mang | Mar 1997 | A |
| 5643173 | Welles | Jul 1997 | A |
| 5775331 | Raymond et al. | Jul 1998 | A |
| 5833709 | Rise et al. | Nov 1998 | A |
| 5833716 | Bar-Or et al. | Nov 1998 | A |
| 5899922 | Loos | May 1999 | A |
| 6016449 | Fischell et al. | Jan 2000 | A |
| 6076018 | Sturman et al. | Jun 2000 | A |
| 6081744 | Loos | Jun 2000 | A |
| 6161044 | Silverstone | Dec 2000 | A |
| 6178352 | Gruzdowich et al. | Jan 2001 | B1 |
| 6351674 | Silverstone | Feb 2002 | B2 |
| 6366813 | DiLorenzo | Apr 2002 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6445955 | Michelson et al. | Sep 2002 | B1 |
| 6449512 | Boveja | Sep 2002 | B1 |
| 6453204 | Rhoads | Sep 2002 | B1 |
| 6505074 | Boveja et al. | Jan 2003 | B2 |
| 6546290 | Shloznikov | Apr 2003 | B1 |
| 6564103 | Fischer et al. | May 2003 | B2 |
| 6579270 | Sussman et al. | Jun 2003 | B2 |
| 6652449 | Gross et al. | Nov 2003 | B1 |
| 6678548 | Echauz et al. | Jan 2004 | B1 |
| 6701185 | Burnett et al. | Mar 2004 | B2 |
| 6704603 | Gesotti | Mar 2004 | B1 |
| 6731987 | McAdams et al. | May 2004 | B1 |
| 6735474 | Loeb et al. | May 2004 | B1 |
| 6735480 | Giuntoli et al. | May 2004 | B2 |
| 6788976 | Gesotti | Sep 2004 | B2 |
| 6819956 | DiLorenzo | Nov 2004 | B2 |
| 6829510 | Nathan et al. | Dec 2004 | B2 |
| 6836684 | Rijkhoff et al. | Dec 2004 | B1 |
| 6862480 | Cohen et al. | Mar 2005 | B2 |
| 6892098 | Ayal et al. | May 2005 | B2 |
| 6937905 | Carroll et al. | Aug 2005 | B2 |
| 6959215 | Gliner et al. | Oct 2005 | B2 |
| 6959216 | Faghri | Oct 2005 | B2 |
| 6988005 | McGraw et al. | Jan 2006 | B2 |
| 7010352 | Hogan | Mar 2006 | B2 |
| 7089061 | Grey | Aug 2006 | B2 |
| 7146220 | Dar et al. | Dec 2006 | B2 |
| 7162305 | Tong et al. | Jan 2007 | B2 |
| 7171266 | Gruzdowich et al. | Jan 2007 | B2 |
| 7177694 | Elbaum | Feb 2007 | B2 |
| 7177703 | Boveja et al. | Feb 2007 | B2 |
| 7209787 | DiLorenzo | Apr 2007 | B2 |
| 7228178 | Carroll et al. | Jun 2007 | B2 |
| 7231254 | DiLorenzo | Jun 2007 | B2 |
| 7236830 | Gliner | Jun 2007 | B2 |
| 7254444 | Moore et al. | Aug 2007 | B2 |
| 7277758 | DiLorenzo | Oct 2007 | B2 |
| 7324851 | DiLorenzo | Jan 2008 | B1 |
| 7326235 | Edwards | Feb 2008 | B2 |
| 7328068 | Spinelli et al. | Feb 2008 | B2 |
| 7349739 | Harry et al. | Mar 2008 | B2 |
| 7353064 | Gliner et al. | Apr 2008 | B2 |
| 7369896 | Gesotti | May 2008 | B2 |
| 7499747 | Kieval et al. | Mar 2009 | B2 |
| 7529582 | DiLorenzo | May 2009 | B1 |
| 7558610 | Odderson | Jul 2009 | B1 |
| 7636602 | Baru Fassio et al. | Dec 2009 | B2 |
| 7643880 | Tanagho et al. | Jan 2010 | B2 |
| 7643882 | Boston | Jan 2010 | B2 |
| 7647112 | Tracey et al. | Jan 2010 | B2 |
| 7650190 | Zhou et al. | Jan 2010 | B2 |
| 7657317 | Thacker et al. | Feb 2010 | B2 |
| 7742820 | Wyler et al. | Jun 2010 | B2 |
| 7761166 | Giftakis et al. | Jul 2010 | B2 |
| 7769464 | Gerber et al. | Aug 2010 | B2 |
| 7857771 | Alwan et al. | Dec 2010 | B2 |
| 7899527 | Yun et al. | Mar 2011 | B2 |
| 7899556 | Nathan et al. | Mar 2011 | B2 |
| 7917201 | Gozani et al. | Mar 2011 | B2 |
| 7930034 | Gerber | Apr 2011 | B2 |
| 7949403 | Palermo et al. | May 2011 | B2 |
| 7957814 | Goetz et al. | Jun 2011 | B2 |
| 7974696 | DiLorenzo | Jul 2011 | B1 |
| 7974698 | Tass et al. | Jul 2011 | B2 |
| 7991476 | Nachum | Aug 2011 | B2 |
| 7996088 | Marrosu et al. | Aug 2011 | B2 |
| 7998092 | Avni et al. | Aug 2011 | B2 |
| 8000796 | Tass et al. | Aug 2011 | B2 |
| 8025632 | Einarsson | Sep 2011 | B2 |
| 8046083 | Tegenthoff et al. | Oct 2011 | B2 |
| 8075499 | Nathan et al. | Dec 2011 | B2 |
| 8086318 | Strother et al. | Dec 2011 | B2 |
| 8121694 | Molnar et al. | Feb 2012 | B2 |
| 8145316 | Deem et al. | Mar 2012 | B2 |
| 8165668 | Dacey, Jr. et al. | Apr 2012 | B2 |
| 8165685 | Knutson et al. | Apr 2012 | B1 |
| 8170658 | Dacey, Jr. et al. | May 2012 | B2 |
| 8175718 | Wahlgren et al. | May 2012 | B2 |
| 8187209 | Guiffrida et al. | May 2012 | B1 |
| 8190249 | Gharieb et al. | May 2012 | B1 |
| 8195287 | Dacey, Jr. et al. | Jun 2012 | B2 |
| 8209036 | Nathan et al. | Jun 2012 | B2 |
| 8219188 | Craig | Jul 2012 | B2 |
| 8233988 | Errico et al. | Jul 2012 | B2 |
| 8260439 | Diubaldi et al. | Sep 2012 | B2 |
| 8265763 | Fahey | Sep 2012 | B2 |
| 8301215 | Lee | Oct 2012 | B2 |
| 8306624 | Gerber et al. | Nov 2012 | B2 |
| 8308665 | Harry et al. | Nov 2012 | B2 |
| 8313443 | Tom | Nov 2012 | B2 |
| 8326432 | Kalisek | Dec 2012 | B2 |
| 8343026 | Gardiner et al. | Jan 2013 | B2 |
| 8364257 | Van Den Eerenbeemd et al. | Jan 2013 | B2 |
| 8374701 | Hyde et al. | Feb 2013 | B2 |
| 8380314 | Panken et al. | Feb 2013 | B2 |
| 8382688 | Dar et al. | Feb 2013 | B2 |
| 8391970 | Tracey et al. | Mar 2013 | B2 |
| 8396556 | Libbus et al. | Mar 2013 | B2 |
| 8406841 | Lin et al. | Mar 2013 | B2 |
| 8409116 | Wang et al. | Apr 2013 | B2 |
| 8412338 | Faltys | Apr 2013 | B2 |
| 8414507 | Asada | Apr 2013 | B2 |
| 8417351 | Kilger | Apr 2013 | B2 |
| 8428719 | Napadow | Apr 2013 | B2 |
| 8430805 | Burnett et al. | Apr 2013 | B2 |
| 8435166 | Burnett et al. | May 2013 | B2 |
| 8447411 | Skelton et al. | May 2013 | B2 |
| 8452410 | Emborg et al. | May 2013 | B2 |
| 8463374 | Hudson et al. | Jun 2013 | B2 |
| 8473064 | Castel et al. | Jun 2013 | B2 |
| 8548594 | Thimineur et al. | Oct 2013 | B2 |
| 8571687 | Libbus et al. | Oct 2013 | B2 |
| 8581731 | Purks et al. | Nov 2013 | B2 |
| 8583238 | Heldman et al. | Nov 2013 | B1 |
| 8588884 | Hegde et al. | Nov 2013 | B2 |
| 8588917 | Whitehurst et al. | Nov 2013 | B2 |
| 8608671 | Kinoshita et al. | Dec 2013 | B2 |
| 8626305 | Nielsen et al. | Jan 2014 | B2 |
| 8639342 | Possover | Jan 2014 | B2 |
| 8644904 | Chang et al. | Feb 2014 | B2 |
| 8644938 | Craggs | Feb 2014 | B2 |
| 8660656 | Moser et al. | Feb 2014 | B2 |
| 8666496 | Simon et al. | Mar 2014 | B2 |
| 8679038 | Giuffrida | Mar 2014 | B1 |
| 8682441 | De Ridder | Mar 2014 | B2 |
| 8688220 | Degiorgio et al. | Apr 2014 | B2 |
| 8694104 | Libbus et al. | Apr 2014 | B2 |
| 8694110 | Nathan et al. | Apr 2014 | B2 |
| 8702584 | Rigaux et al. | Apr 2014 | B2 |
| 8702629 | Giuffrida et al. | Apr 2014 | B2 |
| 8706241 | Firlik et al. | Apr 2014 | B2 |
| 8718780 | Lee | May 2014 | B2 |
| 8738143 | Tucker et al. | May 2014 | B2 |
| 8740825 | Ehrenreich et al. | Jun 2014 | B2 |
| 8744587 | Miesel et al. | Jun 2014 | B2 |
| 8755892 | Amurthur et al. | Jun 2014 | B2 |
| 8768452 | Gerber | Jul 2014 | B2 |
| 8788045 | Gross et al. | Jul 2014 | B2 |
| 8788049 | Lasko et al. | Jul 2014 | B2 |
| 8792977 | Kakei et al. | Jul 2014 | B2 |
| 8798698 | Kim et al. | Aug 2014 | B2 |
| 8821416 | Johansson et al. | Sep 2014 | B2 |
| 8825163 | Grill et al. | Sep 2014 | B2 |
| 8825165 | Possover | Sep 2014 | B2 |
| 8843201 | Heldman et al. | Sep 2014 | B1 |
| 8845494 | Whitall et al. | Sep 2014 | B2 |
| 8845557 | Giuffrida et al. | Sep 2014 | B1 |
| 8855775 | Leyde | Oct 2014 | B2 |
| 8862238 | Rahimi et al. | Oct 2014 | B2 |
| 8862247 | Schoendorf et al. | Oct 2014 | B2 |
| 8868177 | Simon et al. | Oct 2014 | B2 |
| 8874227 | Simon et al. | Oct 2014 | B2 |
| 8880175 | Simon | Nov 2014 | B2 |
| 8886321 | Rohrer et al. | Nov 2014 | B2 |
| 8892200 | Wagner et al. | Nov 2014 | B2 |
| 8897870 | De Ridder | Nov 2014 | B2 |
| 8903494 | Goldwasser et al. | Dec 2014 | B2 |
| 8920345 | Greenberg et al. | Dec 2014 | B2 |
| 8923970 | Bar-Yoseph et al. | Dec 2014 | B2 |
| 8948876 | Gozani et al. | Feb 2015 | B2 |
| 8961439 | Yang et al. | Feb 2015 | B2 |
| 8972017 | Dar et al. | Mar 2015 | B2 |
| 8989861 | Su et al. | Mar 2015 | B2 |
| 9002477 | Burnett | Apr 2015 | B2 |
| 9005102 | Burnett et al. | Apr 2015 | B2 |
| 9008781 | Ahmed | Apr 2015 | B2 |
| 9011310 | Ahmed | Apr 2015 | B2 |
| 9017273 | Burbank et al. | Apr 2015 | B2 |
| 9026216 | Rossi et al. | May 2015 | B2 |
| 9042988 | Dilorenzo | May 2015 | B2 |
| 9060747 | Salorio | Jun 2015 | B2 |
| 9089691 | Libbus et al. | Jul 2015 | B2 |
| 9095351 | Sachs et al. | Aug 2015 | B2 |
| 9095417 | Dar et al. | Aug 2015 | B2 |
| 9107614 | Halkias et al. | Aug 2015 | B2 |
| 9119964 | Marnfeldt | Sep 2015 | B2 |
| 9155885 | Wei et al. | Oct 2015 | B2 |
| 9155890 | Guntinas-Lichius et al. | Oct 2015 | B2 |
| 9162059 | Lindenthaler | Oct 2015 | B1 |
| 9168374 | Su | Oct 2015 | B2 |
| 9174045 | Simon et al. | Nov 2015 | B2 |
| 9186095 | Machado et al. | Nov 2015 | B2 |
| 9192763 | Gerber et al. | Nov 2015 | B2 |
| 9220431 | Holzhacker | Dec 2015 | B2 |
| 9220895 | Siff et al. | Dec 2015 | B2 |
| 9227056 | Heldman et al. | Jan 2016 | B1 |
| 9238137 | Einav et al. | Jan 2016 | B2 |
| 9238142 | Heldman et al. | Jan 2016 | B2 |
| 9242085 | Hershey et al. | Jan 2016 | B2 |
| 9248285 | Haessler | Feb 2016 | B2 |
| 9248286 | Simon et al. | Feb 2016 | B2 |
| 9248297 | Hoyer et al. | Feb 2016 | B2 |
| 9254382 | Ahmad et al. | Feb 2016 | B2 |
| 9259577 | Kaula et al. | Feb 2016 | B2 |
| 9265927 | Yonce et al. | Feb 2016 | B2 |
| 9282928 | Giffrida | Mar 2016 | B1 |
| 9289607 | Su et al. | Mar 2016 | B2 |
| 9301712 | McNames et al. | Apr 2016 | B2 |
| 9302046 | Giuffrida et al. | Apr 2016 | B1 |
| 9311686 | Roush et al. | Apr 2016 | B2 |
| 9314190 | Giuffrida et al. | Apr 2016 | B1 |
| 9314622 | Embrey et al. | Apr 2016 | B2 |
| 9332918 | Buckley et al. | May 2016 | B1 |
| 9339213 | Otsamo et al. | May 2016 | B2 |
| 9339641 | Rajguru et al. | May 2016 | B2 |
| 9345872 | Groteke | May 2016 | B2 |
| 9364657 | Kiani et al. | Jun 2016 | B2 |
| 9364672 | Marnfeldt | Jun 2016 | B2 |
| 9375570 | Kiani et al. | Jun 2016 | B2 |
| 9387338 | Burnett | Jul 2016 | B2 |
| 9393430 | Demers et al. | Jul 2016 | B2 |
| 9408683 | St. Anne et al. | Aug 2016 | B2 |
| 9414776 | Sillay et al. | Aug 2016 | B2 |
| 9415205 | Lasko et al. | Aug 2016 | B2 |
| 9452287 | Rosenbluth et al. | Sep 2016 | B2 |
| 9468753 | Fisher et al. | Oct 2016 | B2 |
| 9474898 | Gozani et al. | Oct 2016 | B2 |
| 9549872 | Chen et al. | Jan 2017 | B2 |
| 9581972 | Arrow et al. | Feb 2017 | B1 |
| 9586038 | Kosierkiewicz | Mar 2017 | B1 |
| 9589698 | Anhalt et al. | Mar 2017 | B2 |
| 9597509 | Hoffer et al. | Mar 2017 | B2 |
| 9610442 | Yoo et al. | Apr 2017 | B2 |
| 9610459 | Burnett et al. | Apr 2017 | B2 |
| 9615797 | John | Apr 2017 | B2 |
| 9630004 | Rajguru et al. | Apr 2017 | B2 |
| 9649486 | Holzhacker | May 2017 | B2 |
| 9656070 | Gozani et al. | May 2017 | B2 |
| 9669211 | Wijting et al. | Jun 2017 | B2 |
| 9675800 | Li et al. | Jun 2017 | B2 |
| 9675801 | Kong et al. | Jun 2017 | B2 |
| 9707393 | Hsueh et al. | Jul 2017 | B2 |
| 9731126 | Ferree et al. | Aug 2017 | B2 |
| 9757584 | Burnett | Sep 2017 | B2 |
| 9782584 | Cartledge et al. | Oct 2017 | B2 |
| 9802041 | Wong et al. | Oct 2017 | B2 |
| 9861283 | Giuffrida | Jan 2018 | B1 |
| 9877679 | Giuffrida | Jan 2018 | B1 |
| 9877680 | Giuffrida et al. | Jan 2018 | B1 |
| 9884179 | Bouton et al. | Feb 2018 | B2 |
| 9924899 | Pracar et al. | Mar 2018 | B2 |
| 9956395 | Bikson et al. | May 2018 | B2 |
| 9974478 | Brokaw et al. | May 2018 | B1 |
| 9980659 | Sadeghian-Motahar et al. | May 2018 | B2 |
| 9992918 | Watanabe et al. | Jun 2018 | B2 |
| 10004900 | Kent et al. | Jun 2018 | B2 |
| 10016600 | Creasey et al. | Jul 2018 | B2 |
| 10022545 | Giuffrida | Jul 2018 | B1 |
| 10028695 | Machado et al. | Jul 2018 | B2 |
| 10045740 | John | Aug 2018 | B2 |
| 10046161 | Biasiucci et al. | Aug 2018 | B2 |
| 10076656 | Dar et al. | Sep 2018 | B2 |
| 10080885 | Nathan et al. | Sep 2018 | B2 |
| 10112040 | Herb et al. | Oct 2018 | B2 |
| 10118035 | Perez et al. | Nov 2018 | B2 |
| 10130809 | Cartledge et al. | Nov 2018 | B2 |
| 10130810 | Ferree et al. | Nov 2018 | B2 |
| 10137025 | Fior et al. | Nov 2018 | B2 |
| 10173060 | Wong et al. | Jan 2019 | B2 |
| 10179238 | Wong et al. | Jan 2019 | B2 |
| 10213593 | Kaplan et al. | Feb 2019 | B2 |
| 10213602 | Ironi et al. | Feb 2019 | B2 |
| 10232174 | Simon et al. | Mar 2019 | B2 |
| 10252053 | Page et al. | Apr 2019 | B2 |
| 10285646 | Grant et al. | May 2019 | B1 |
| 10286210 | Yoo | May 2019 | B2 |
| 10293159 | Kong et al. | May 2019 | B2 |
| 10335594 | Lin et al. | Jul 2019 | B2 |
| 10335595 | Ferree et al. | Jul 2019 | B2 |
| 10342977 | Raghunathan | Jul 2019 | B2 |
| 10398896 | Lin et al. | Sep 2019 | B2 |
| 10456573 | Feinstein et al. | Oct 2019 | B1 |
| 10463854 | Perez | Nov 2019 | B2 |
| 10500396 | Tamaki et al. | Dec 2019 | B2 |
| 10537732 | Nachum et al. | Jan 2020 | B2 |
| 10549093 | Wong et al. | Feb 2020 | B2 |
| 10556107 | Yoo et al. | Feb 2020 | B2 |
| 10561839 | Wong et al. | Feb 2020 | B2 |
| 10603482 | Hamner et al. | Mar 2020 | B2 |
| 10610114 | Buckley et al. | Apr 2020 | B2 |
| 10625074 | Rosenbluth et al. | Apr 2020 | B2 |
| 10632312 | Ziv | Apr 2020 | B2 |
| 10661082 | Kerselaers | May 2020 | B2 |
| 10722709 | Yoo et al. | Jul 2020 | B2 |
| 10765856 | Wong et al. | Sep 2020 | B2 |
| 10773079 | Keller et al. | Sep 2020 | B2 |
| 10780269 | Gozani et al. | Sep 2020 | B2 |
| 10786669 | Rajguru et al. | Sep 2020 | B2 |
| 10814130 | Wong et al. | Oct 2020 | B2 |
| 10814131 | Goldwasser et al. | Oct 2020 | B2 |
| 10835736 | Horter et al. | Nov 2020 | B2 |
| 10850090 | Rosenbluth et al. | Dec 2020 | B2 |
| 10870002 | Wybo et al. | Dec 2020 | B2 |
| 10905879 | Wong et al. | Feb 2021 | B2 |
| 10918853 | Creasey et al. | Feb 2021 | B2 |
| 10940311 | Gozani et al. | Mar 2021 | B2 |
| 10945879 | Black et al. | Mar 2021 | B2 |
| 10960207 | Wong et al. | Mar 2021 | B2 |
| 10967177 | Lee | Apr 2021 | B2 |
| 11026835 | Black et al. | Jun 2021 | B2 |
| 11033206 | Roh | Jun 2021 | B2 |
| 11033731 | Jeffery et al. | Jun 2021 | B2 |
| 11033736 | Edgerton et al. | Jun 2021 | B2 |
| 11058867 | Nathan et al. | Jul 2021 | B2 |
| 11077300 | McBride | Aug 2021 | B2 |
| 11077301 | Creasey et al. | Aug 2021 | B2 |
| 11103699 | Oppenheim et al. | Aug 2021 | B1 |
| 11141586 | Campean et al. | Oct 2021 | B2 |
| 11141587 | Campean et al. | Oct 2021 | B2 |
| 11160971 | Sharma et al. | Nov 2021 | B2 |
| 11213681 | Raghunathan | Jan 2022 | B2 |
| 11224742 | Burnett | Jan 2022 | B2 |
| 11247040 | Ferree et al. | Feb 2022 | B2 |
| 11247053 | Rajguru et al. | Feb 2022 | B2 |
| 11266836 | Charlesworth et al. | Mar 2022 | B2 |
| 11331480 | Hamner et al. | May 2022 | B2 |
| 11344722 | Wong et al. | May 2022 | B2 |
| 11357981 | Moaddeb et al. | Jun 2022 | B2 |
| 11596785 | Hamner et al. | Mar 2023 | B2 |
| 11596791 | Wong et al. | Mar 2023 | B2 |
| 11628300 | Rajguru et al. | Apr 2023 | B2 |
| 11857778 | Hamner et al. | Jan 2024 | B2 |
| 11890468 | Yu | Feb 2024 | B1 |
| 11918806 | Wong et al. | Mar 2024 | B2 |
| 20010020177 | Gruzdowich et al. | Sep 2001 | A1 |
| 20020055761 | Mann et al. | May 2002 | A1 |
| 20020161415 | Cohen et al. | Oct 2002 | A1 |
| 20020165586 | Hill et al. | Nov 2002 | A1 |
| 20020177882 | DiLorenzo | Nov 2002 | A1 |
| 20030032992 | Thacker et al. | Feb 2003 | A1 |
| 20030045922 | Northrop | Mar 2003 | A1 |
| 20030088294 | Gesotti | May 2003 | A1 |
| 20030093098 | Heitzmann et al. | May 2003 | A1 |
| 20030149457 | Tcheng et al. | Aug 2003 | A1 |
| 20030181959 | Dobak, III | Sep 2003 | A1 |
| 20030187483 | Grey et al. | Oct 2003 | A1 |
| 20030195583 | Gruzdowich et al. | Oct 2003 | A1 |
| 20040015094 | Manabe et al. | Jan 2004 | A1 |
| 20040088025 | Gessotti | May 2004 | A1 |
| 20040093093 | Andrews | May 2004 | A1 |
| 20040102819 | Zou et al. | May 2004 | A1 |
| 20040127939 | Grey et al. | Jul 2004 | A1 |
| 20040133249 | Gesotti | Jul 2004 | A1 |
| 20040167588 | Bertolucci | Aug 2004 | A1 |
| 20040249416 | Yun et al. | Dec 2004 | A1 |
| 20040267331 | Koeneman et al. | Dec 2004 | A1 |
| 20050021103 | DiLorenzo | Jan 2005 | A1 |
| 20050055063 | Loeb et al. | Mar 2005 | A1 |
| 20050060009 | Geotz | Mar 2005 | A1 |
| 20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
| 20050075502 | Shafer | Apr 2005 | A1 |
| 20050171576 | Williams et al. | Aug 2005 | A1 |
| 20050171577 | Cohen et al. | Aug 2005 | A1 |
| 20050182454 | Gharib et al. | Aug 2005 | A1 |
| 20050222626 | DiLorenzo | Oct 2005 | A1 |
| 20050234309 | Klapper | Oct 2005 | A1 |
| 20050240241 | Yun et al. | Oct 2005 | A1 |
| 20060015153 | Gliner et al. | Jan 2006 | A1 |
| 20060047326 | Wheeler | Mar 2006 | A1 |
| 20060052726 | Weisz et al. | Mar 2006 | A1 |
| 20060074450 | Boveja et al. | Apr 2006 | A1 |
| 20060095088 | De Ridder | May 2006 | A1 |
| 20060161218 | Danilov | Jul 2006 | A1 |
| 20060173509 | Lee et al. | Aug 2006 | A1 |
| 20060184059 | Jadidi | Aug 2006 | A1 |
| 20060217781 | John | Sep 2006 | A1 |
| 20060224191 | DiLorenzo | Oct 2006 | A1 |
| 20060229678 | Lee | Oct 2006 | A1 |
| 20060253167 | Kurtz et al. | Nov 2006 | A1 |
| 20060276853 | Tass | Dec 2006 | A1 |
| 20060293723 | Whitehurst et al. | Dec 2006 | A1 |
| 20070027486 | Armstrong | Feb 2007 | A1 |
| 20070073361 | Goren et al. | Mar 2007 | A1 |
| 20070123951 | Boston | May 2007 | A1 |
| 20070123952 | Strother et al. | May 2007 | A1 |
| 20070142862 | DiLorenzo | Jun 2007 | A1 |
| 20070156179 | Karashurov | Jul 2007 | A1 |
| 20070156182 | Castel et al. | Jul 2007 | A1 |
| 20070156183 | Rhodes | Jul 2007 | A1 |
| 20070156200 | Kornet et al. | Jul 2007 | A1 |
| 20070173899 | Levin et al. | Jul 2007 | A1 |
| 20070173903 | Goren et al. | Jul 2007 | A1 |
| 20070203533 | Goren et al. | Aug 2007 | A1 |
| 20070203534 | Tapper | Aug 2007 | A1 |
| 20070207193 | Zasler et al. | Sep 2007 | A1 |
| 20070249952 | Rubin et al. | Oct 2007 | A1 |
| 20070255319 | Greenberg et al. | Nov 2007 | A1 |
| 20070276217 | Brown et al. | Nov 2007 | A1 |
| 20070282228 | Einav et al. | Dec 2007 | A1 |
| 20080004672 | Dalal et al. | Jan 2008 | A1 |
| 20080009772 | Tyler et al. | Jan 2008 | A1 |
| 20080021505 | Hastings et al. | Jan 2008 | A1 |
| 20080027507 | Bijelic et al. | Jan 2008 | A1 |
| 20080030170 | Dacuay et al. | Feb 2008 | A1 |
| 20080033259 | Manto et al. | Feb 2008 | A1 |
| 20080033504 | Bertolucci | Feb 2008 | A1 |
| 20080051839 | Libbus et al. | Feb 2008 | A1 |
| 20080051845 | Mentelos | Feb 2008 | A1 |
| 20080058773 | John | Mar 2008 | A1 |
| 20080058871 | Libbus et al. | Mar 2008 | A1 |
| 20080058893 | Noujokat | Mar 2008 | A1 |
| 20080097564 | Lathrop | Apr 2008 | A1 |
| 20080147146 | Wahlgren et al. | Jun 2008 | A1 |
| 20080177398 | Gross et al. | Jul 2008 | A1 |
| 20080195007 | Podrazhansky et al. | Aug 2008 | A1 |
| 20080208282 | Gelfand et al. | Aug 2008 | A1 |
| 20080208288 | Podrazhansky et al. | Aug 2008 | A1 |
| 20080216593 | Jacobsen et al. | Sep 2008 | A1 |
| 20080243204 | Uthman et al. | Oct 2008 | A1 |
| 20080288016 | Amurthur et al. | Nov 2008 | A1 |
| 20080300449 | Gerber et al. | Dec 2008 | A1 |
| 20080306325 | Burnett et al. | Dec 2008 | A1 |
| 20080312520 | Rowlandson et al. | Dec 2008 | A1 |
| 20090018609 | DiLorenzo | Jan 2009 | A1 |
| 20090076565 | Surwit | Mar 2009 | A1 |
| 20090082831 | Paul et al. | Mar 2009 | A1 |
| 20090099623 | Bentwich | Apr 2009 | A1 |
| 20090105785 | Wei et al. | Apr 2009 | A1 |
| 20090112133 | Deisseroth et al. | Apr 2009 | A1 |
| 20090157138 | Errico et al. | Jun 2009 | A1 |
| 20090187121 | Evans | Jul 2009 | A1 |
| 20090216294 | Ewing et al. | Aug 2009 | A1 |
| 20090222053 | Gaunt et al. | Sep 2009 | A1 |
| 20090247910 | Klapper | Oct 2009 | A1 |
| 20090249617 | Karicherla et al. | Oct 2009 | A1 |
| 20090299435 | Gliner et al. | Dec 2009 | A1 |
| 20090312690 | Kim et al. | Dec 2009 | A1 |
| 20090318986 | Alo et al. | Dec 2009 | A1 |
| 20090326595 | Brockway et al. | Dec 2009 | A1 |
| 20090326607 | Castel et al. | Dec 2009 | A1 |
| 20100004715 | Fahey | Jan 2010 | A1 |
| 20100010381 | Skelton et al. | Jan 2010 | A1 |
| 20100010383 | Skelton et al. | Jan 2010 | A1 |
| 20100010572 | Skelton et al. | Jan 2010 | A1 |
| 20100057154 | Dietrich et al. | Mar 2010 | A1 |
| 20100059722 | Copp-Howland et al. | Mar 2010 | A1 |
| 20100076533 | Dar et al. | Mar 2010 | A1 |
| 20100099963 | Kilger | Apr 2010 | A1 |
| 20100107657 | Vistakula | May 2010 | A1 |
| 20100125220 | Seong | May 2010 | A1 |
| 20100152817 | Gillbe | Jun 2010 | A1 |
| 20100168501 | Burnett et al. | Jul 2010 | A1 |
| 20100168604 | Echauz | Jul 2010 | A1 |
| 20100174342 | Boston et al. | Jul 2010 | A1 |
| 20100222630 | Mangrum et al. | Sep 2010 | A1 |
| 20100227330 | Fink et al. | Sep 2010 | A1 |
| 20100228180 | Jayes et al. | Sep 2010 | A1 |
| 20100249637 | Walter et al. | Sep 2010 | A1 |
| 20100292527 | Schneider et al. | Nov 2010 | A1 |
| 20100298905 | Simon | Nov 2010 | A1 |
| 20100324611 | Deming et al. | Dec 2010 | A1 |
| 20110004268 | Tcheng et al. | Jan 2011 | A1 |
| 20110009920 | Whitehurst et al. | Jan 2011 | A1 |
| 20110021899 | Arps et al. | Jan 2011 | A1 |
| 20110040204 | Ivorra et al. | Feb 2011 | A1 |
| 20110040288 | Eckstein et al. | Feb 2011 | A1 |
| 20110054358 | Kim et al. | Mar 2011 | A1 |
| 20110071590 | Mounaim et al. | Mar 2011 | A1 |
| 20110098780 | Graupe et al. | Apr 2011 | A1 |
| 20110112605 | Fahey | May 2011 | A1 |
| 20110118805 | Wei et al. | May 2011 | A1 |
| 20110125212 | Tyler | May 2011 | A1 |
| 20110137375 | McBride | Jun 2011 | A1 |
| 20110184489 | Nicolelis et al. | Jul 2011 | A1 |
| 20110196446 | Wu | Aug 2011 | A1 |
| 20110202107 | Sunagawa et al. | Aug 2011 | A1 |
| 20110208444 | Solinky | Aug 2011 | A1 |
| 20110213278 | Horak et al. | Sep 2011 | A1 |
| 20110224571 | Pascual-Leone et al. | Sep 2011 | A1 |
| 20110230701 | Simon et al. | Sep 2011 | A1 |
| 20110245734 | Wagner et al. | Oct 2011 | A1 |
| 20110250297 | Oronsky et al. | Oct 2011 | A1 |
| 20110282412 | Glukhovsky et al. | Nov 2011 | A1 |
| 20110288615 | Armstrong et al. | Nov 2011 | A1 |
| 20110301663 | Wang et al. | Dec 2011 | A1 |
| 20120010492 | Thramann et al. | Jan 2012 | A1 |
| 20120046535 | Lin et al. | Feb 2012 | A1 |
| 20120050298 | Hoffman | Mar 2012 | A1 |
| 20120053491 | Nathan et al. | Mar 2012 | A1 |
| 20120059298 | Hoffman et al. | Mar 2012 | A1 |
| 20120078319 | De Ridder | Mar 2012 | A1 |
| 20120088986 | David et al. | Apr 2012 | A1 |
| 20120092178 | Callsen et al. | Apr 2012 | A1 |
| 20120098493 | Budike | Apr 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120109013 | Everett et al. | May 2012 | A1 |
| 20120136410 | Rezai et al. | May 2012 | A1 |
| 20120158094 | Kramer et al. | Jun 2012 | A1 |
| 20120184801 | Simon et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120211013 | Otis | Aug 2012 | A1 |
| 20120220812 | Mishelevich | Aug 2012 | A1 |
| 20120239112 | Muraoka | Sep 2012 | A1 |
| 20120245483 | Lundqvist | Sep 2012 | A1 |
| 20120259255 | Tomlinson et al. | Oct 2012 | A1 |
| 20120277621 | Gerber et al. | Nov 2012 | A1 |
| 20120289869 | Tyler | Nov 2012 | A1 |
| 20120290036 | Karamanoglu et al. | Nov 2012 | A1 |
| 20120302821 | Burnett | Nov 2012 | A1 |
| 20120310298 | Besio et al. | Dec 2012 | A1 |
| 20120310299 | Norbert et al. | Dec 2012 | A1 |
| 20120310303 | Popovic et al. | Dec 2012 | A1 |
| 20120330182 | Alberts et al. | Dec 2012 | A1 |
| 20130006322 | Tai | Jan 2013 | A1 |
| 20130035745 | Ahmed et al. | Feb 2013 | A1 |
| 20130053817 | Yun et al. | Feb 2013 | A1 |
| 20130060124 | Zietsma | Mar 2013 | A1 |
| 20130066388 | Bernhard et al. | Mar 2013 | A1 |
| 20130066395 | Simon et al. | Mar 2013 | A1 |
| 20130085317 | Feinstein | Apr 2013 | A1 |
| 20130090519 | Tass | Apr 2013 | A1 |
| 20130106684 | Weast et al. | May 2013 | A1 |
| 20130116606 | Cordo | May 2013 | A1 |
| 20130123568 | Hamilton et al. | May 2013 | A1 |
| 20130123666 | Giuffrida et al. | May 2013 | A1 |
| 20130131484 | Pernu | May 2013 | A1 |
| 20130131770 | Rezai | May 2013 | A1 |
| 20130158624 | Bain et al. | Jun 2013 | A1 |
| 20130158627 | Gozani et al. | Jun 2013 | A1 |
| 20130178765 | Mishelevich | Jul 2013 | A1 |
| 20130211471 | Libbus et al. | Aug 2013 | A1 |
| 20130231713 | De Ridder et al. | Sep 2013 | A1 |
| 20130236867 | Avni et al. | Sep 2013 | A1 |
| 20130238049 | Simon et al. | Sep 2013 | A1 |
| 20130245486 | Simon et al. | Sep 2013 | A1 |
| 20130245713 | Tass | Sep 2013 | A1 |
| 20130253299 | Weber et al. | Sep 2013 | A1 |
| 20130267759 | Jin | Oct 2013 | A1 |
| 20130281890 | Mishelevich | Oct 2013 | A1 |
| 20130289647 | Bhadra et al. | Oct 2013 | A1 |
| 20130296967 | Skaribas et al. | Nov 2013 | A1 |
| 20130297022 | Pathak | Nov 2013 | A1 |
| 20130331907 | Sumners et al. | Dec 2013 | A1 |
| 20130333094 | Rogers et al. | Dec 2013 | A1 |
| 20130338726 | Machado | Dec 2013 | A1 |
| 20140025059 | Kerr | Jan 2014 | A1 |
| 20140031605 | Schneider | Jan 2014 | A1 |
| 20140039573 | Jindra | Feb 2014 | A1 |
| 20140039575 | Bradley | Feb 2014 | A1 |
| 20140046423 | Rajguru et al. | Feb 2014 | A1 |
| 20140058189 | Stubbeman | Feb 2014 | A1 |
| 20140067003 | Vase et al. | Mar 2014 | A1 |
| 20140078694 | Wissmar | Mar 2014 | A1 |
| 20140081345 | Hershey | Mar 2014 | A1 |
| 20140094675 | Luna et al. | Apr 2014 | A1 |
| 20140094873 | Emborg et al. | Apr 2014 | A1 |
| 20140128939 | Embrey et al. | May 2014 | A1 |
| 20140132410 | Chang | May 2014 | A1 |
| 20140142654 | Simon et al. | May 2014 | A1 |
| 20140148872 | Goldwasser et al. | May 2014 | A1 |
| 20140148873 | Kirn | May 2014 | A1 |
| 20140163444 | Ingvarsson | Jun 2014 | A1 |
| 20140171834 | DeGoede et al. | Jun 2014 | A1 |
| 20140200573 | Deem et al. | Jul 2014 | A1 |
| 20140214119 | Greiner et al. | Jul 2014 | A1 |
| 20140228927 | Ahmad et al. | Aug 2014 | A1 |
| 20140236258 | Carroll et al. | Aug 2014 | A1 |
| 20140246628 | Anhalt et al. | Sep 2014 | A1 |
| 20140249452 | Marsh et al. | Sep 2014 | A1 |
| 20140257047 | Sillay et al. | Sep 2014 | A1 |
| 20140257129 | Choi et al. | Sep 2014 | A1 |
| 20140276194 | Osorio | Sep 2014 | A1 |
| 20140277220 | Brennan et al. | Sep 2014 | A1 |
| 20140296752 | Edgerton et al. | Oct 2014 | A1 |
| 20140296934 | Gozani et al. | Oct 2014 | A1 |
| 20140296935 | Ferree et al. | Oct 2014 | A1 |
| 20140300490 | Kotz et al. | Oct 2014 | A1 |
| 20140309709 | Gozanl et al. | Oct 2014 | A1 |
| 20140316484 | Edgerton et al. | Oct 2014 | A1 |
| 20140324118 | Simon et al. | Oct 2014 | A1 |
| 20140330068 | Partsch et al. | Nov 2014 | A1 |
| 20140330335 | Errico et al. | Nov 2014 | A1 |
| 20140336003 | Franz et al. | Nov 2014 | A1 |
| 20140336722 | Rocon De Lima et al. | Nov 2014 | A1 |
| 20140343462 | Burnet | Nov 2014 | A1 |
| 20140350436 | Nathan et al. | Nov 2014 | A1 |
| 20140358040 | Kim et al. | Dec 2014 | A1 |
| 20140364678 | Harry et al. | Dec 2014 | A1 |
| 20150004656 | Tang et al. | Jan 2015 | A1 |
| 20150005852 | Hershey et al. | Jan 2015 | A1 |
| 20150012067 | Bradley et al. | Jan 2015 | A1 |
| 20150038886 | Snow | Feb 2015 | A1 |
| 20150042315 | Cen et al. | Feb 2015 | A1 |
| 20150044656 | Eichhorn et al. | Feb 2015 | A1 |
| 20150057506 | Luna et al. | Feb 2015 | A1 |
| 20150073310 | Pracar et al. | Mar 2015 | A1 |
| 20150080979 | Lasko et al. | Mar 2015 | A1 |
| 20150100004 | Goldman et al. | Apr 2015 | A1 |
| 20150100104 | Kiani et al. | Apr 2015 | A1 |
| 20150100105 | Kiani et al. | Apr 2015 | A1 |
| 20150148866 | Bulsen et al. | May 2015 | A1 |
| 20150148878 | Yoo et al. | May 2015 | A1 |
| 20150157274 | Ghassemzadeh et al. | Jun 2015 | A1 |
| 20150164377 | Nathan et al. | Jun 2015 | A1 |
| 20150164401 | Toth et al. | Jun 2015 | A1 |
| 20150190085 | Nathan et al. | Jul 2015 | A1 |
| 20150190634 | Rezai et al. | Jul 2015 | A1 |
| 20150196767 | Zaghloul | Jul 2015 | A1 |
| 20150202444 | Franke et al. | Jul 2015 | A1 |
| 20150208955 | Smith | Jul 2015 | A1 |
| 20150216475 | Luna et al. | Aug 2015 | A1 |
| 20150230733 | Heo et al. | Aug 2015 | A1 |
| 20150230756 | Luna et al. | Aug 2015 | A1 |
| 20150277559 | Vescovi et al. | Oct 2015 | A1 |
| 20150297901 | Kockx | Oct 2015 | A1 |
| 20150321000 | Rosenbluth et al. | Nov 2015 | A1 |
| 20150335882 | Gross et al. | Nov 2015 | A1 |
| 20160001096 | Mishelevich | Jan 2016 | A1 |
| 20160008620 | Stubbeman | Jan 2016 | A1 |
| 20160016014 | Wagner et al. | Jan 2016 | A1 |
| 20160022987 | Zschaeck et al. | Jan 2016 | A1 |
| 20160022989 | Pfeifer | Jan 2016 | A1 |
| 20160038059 | Asada et al. | Feb 2016 | A1 |
| 20160045140 | Kitamura et al. | Feb 2016 | A1 |
| 20160089045 | Sadeghian-Motahar et al. | Mar 2016 | A1 |
| 20160106344 | Nazari | Apr 2016 | A1 |
| 20160121110 | Kent et al. | May 2016 | A1 |
| 20160128621 | Machado et al. | May 2016 | A1 |
| 20160129248 | Creasey et al. | May 2016 | A1 |
| 20160158542 | Ahmed | Jun 2016 | A1 |
| 20160158565 | Lee | Jun 2016 | A1 |
| 20160198998 | Rahimi et al. | Jul 2016 | A1 |
| 20160213924 | Coleman et al. | Jul 2016 | A1 |
| 20160220836 | Parks | Aug 2016 | A1 |
| 20160262685 | Wagner et al. | Sep 2016 | A1 |
| 20160263376 | Yoo et al. | Sep 2016 | A1 |
| 20160279435 | Hyde et al. | Sep 2016 | A1 |
| 20160287879 | Denison et al. | Oct 2016 | A1 |
| 20160039239 | Yoo et al. | Nov 2016 | A1 |
| 20160336722 | Taxter | Nov 2016 | A1 |
| 20160339239 | Yoo et al. | Nov 2016 | A1 |
| 20160361540 | Simon et al. | Dec 2016 | A9 |
| 20160375249 | Bonnet et al. | Dec 2016 | A1 |
| 20170014625 | Rosenbluth et al. | Jan 2017 | A1 |
| 20170027812 | Hyde et al. | Feb 2017 | A1 |
| 20170042467 | Herr et al. | Feb 2017 | A1 |
| 20170056238 | Yi et al. | Mar 2017 | A1 |
| 20170056643 | Herb et al. | Mar 2017 | A1 |
| 20170079597 | Horne | Mar 2017 | A1 |
| 20170080207 | Perez et al. | Mar 2017 | A1 |
| 20170095667 | Yakovlev et al. | Apr 2017 | A1 |
| 20170113045 | Baldassano et al. | Apr 2017 | A1 |
| 20170128722 | Perez | May 2017 | A1 |
| 20170157398 | Wong et al. | Jun 2017 | A1 |
| 20170165485 | Sullivan et al. | Jun 2017 | A1 |
| 20170132067 | Wong et al. | Aug 2017 | A1 |
| 20170224991 | Wingeier et al. | Aug 2017 | A1 |
| 20170239415 | Hwang et al. | Aug 2017 | A1 |
| 20170246481 | Mishelevich | Aug 2017 | A1 |
| 20170266443 | Rajguru et al. | Sep 2017 | A1 |
| 20170274208 | Nagel et al. | Sep 2017 | A1 |
| 20170287146 | Pathak et al. | Oct 2017 | A1 |
| 20170312505 | Ahmed | Nov 2017 | A1 |
| 20170312512 | Creasey et al. | Nov 2017 | A1 |
| 20170312513 | Hershey et al. | Nov 2017 | A1 |
| 20170361093 | Yoo et al. | Dec 2017 | A1 |
| 20170368329 | Tyler et al. | Dec 2017 | A1 |
| 20180001086 | Bartholomew et al. | Jan 2018 | A1 |
| 20180001088 | Tass | Jan 2018 | A1 |
| 20180021576 | Wong et al. | Jan 2018 | A1 |
| 20180028841 | Konofagou et al. | Feb 2018 | A1 |
| 20180036535 | Wong et al. | Feb 2018 | A1 |
| 20180042654 | Ingvarsson et al. | Feb 2018 | A1 |
| 20180049676 | Griffiths et al. | Feb 2018 | A1 |
| 20180064344 | Nguyen | Mar 2018 | A1 |
| 20180064362 | Hennings et al. | Mar 2018 | A1 |
| 20180064944 | Grill et al. | Mar 2018 | A1 |
| 20180116546 | Pastoor et al. | May 2018 | A1 |
| 20180132757 | Kong et al. | May 2018 | A1 |
| 20180140842 | Olaighin et al. | May 2018 | A1 |
| 20180168905 | Goodall et al. | Jun 2018 | A1 |
| 20180169400 | Wong et al. | Jun 2018 | A1 |
| 20180214694 | Parramon | Aug 2018 | A1 |
| 20180221620 | Metzger | Aug 2018 | A1 |
| 20180235500 | Lee et al. | Aug 2018 | A1 |
| 20180236217 | Hamner et al. | Aug 2018 | A1 |
| 20180264263 | Rosenbluth et al. | Sep 2018 | A1 |
| 20180345020 | Ironi et al. | Dec 2018 | A1 |
| 20190001117 | Ben-David et al. | Jan 2019 | A1 |
| 20190001129 | Rosenbluth et al. | Jan 2019 | A1 |
| 20190001139 | Mishra et al. | Jan 2019 | A1 |
| 20190126047 | Kassiri Bidhendi et al. | May 2019 | A1 |
| 20190134393 | Wong et al. | May 2019 | A1 |
| 20190143098 | Kaplan et al. | May 2019 | A1 |
| 20190143111 | Hamner et al. | May 2019 | A1 |
| 20190143113 | Wong et al. | May 2019 | A1 |
| 20190167976 | Byers et al. | Jun 2019 | A1 |
| 20190269914 | Moaddeb et al. | Sep 2019 | A1 |
| 20190298998 | Coleman et al. | Oct 2019 | A1 |
| 20190321636 | Law | Oct 2019 | A1 |
| 20190343462 | Grant et al. | Nov 2019 | A1 |
| 20190374771 | Simon et al. | Dec 2019 | A1 |
| 20200023183 | Ollerenshaw et al. | Jan 2020 | A1 |
| 20200038654 | Doskocil et al. | Feb 2020 | A1 |
| 20200046968 | Herr et al. | Feb 2020 | A1 |
| 20200061378 | Ganguly et al. | Feb 2020 | A1 |
| 20200093400 | Hamner et al. | Mar 2020 | A1 |
| 20200139118 | John et al. | May 2020 | A1 |
| 20200147373 | Tamaki et al. | May 2020 | A1 |
| 20200155847 | Perez | May 2020 | A1 |
| 20200171269 | Hooper et al. | Jun 2020 | A1 |
| 20200171304 | Simon et al. | Jun 2020 | A1 |
| 20200179687 | Wong et al. | Jun 2020 | A1 |
| 20200197707 | Covalin | Jun 2020 | A1 |
| 20200215324 | Mantovani et al. | Jul 2020 | A1 |
| 20200221975 | Basta et al. | Jul 2020 | A1 |
| 20200254247 | Brezel et al. | Aug 2020 | A1 |
| 20200254251 | Wong et al. | Aug 2020 | A1 |
| 20200269046 | Page et al. | Aug 2020 | A1 |
| 20200276442 | Owen | Sep 2020 | A1 |
| 20200282201 | Doskocil | Sep 2020 | A1 |
| 20200289813 | Ito et al. | Sep 2020 | A1 |
| 20200289814 | Hamner et al. | Sep 2020 | A1 |
| 20200297999 | Pal | Sep 2020 | A1 |
| 20200316379 | Yoo et al. | Oct 2020 | A1 |
| 20200324104 | Labuschagne et al. | Oct 2020 | A1 |
| 20200338348 | Honeycutt et al. | Oct 2020 | A1 |
| 20200367775 | Buckley et al. | Nov 2020 | A1 |
| 20200405188 | Sharma et al. | Dec 2020 | A1 |
| 20200406022 | Sharma et al. | Dec 2020 | A1 |
| 20210016079 | Ekelem et al. | Jan 2021 | A1 |
| 20210031026 | Simon et al. | Feb 2021 | A1 |
| 20210031036 | Sharma et al. | Feb 2021 | A1 |
| 20210052883 | Wong et al. | Feb 2021 | A1 |
| 20210052897 | Bhadra et al. | Feb 2021 | A1 |
| 20210052900 | Pepin et al. | Feb 2021 | A1 |
| 20210060337 | Wybo et al. | Mar 2021 | A1 |
| 20210069507 | Gozani et al. | Mar 2021 | A1 |
| 20210100999 | Rosenbluth et al. | Apr 2021 | A1 |
| 20210101007 | Hamner et al. | Apr 2021 | A1 |
| 20210113834 | Wong et al. | Apr 2021 | A1 |
| 20210162212 | Kern et al. | Jun 2021 | A1 |
| 20210169684 | Black et al. | Jun 2021 | A1 |
| 20210187279 | Bouton et al. | Jun 2021 | A1 |
| 20210205619 | Wong et al. | Jul 2021 | A1 |
| 20210213283 | Yoo et al. | Jul 2021 | A1 |
| 20210220650 | Kassiri Bidhendi et al. | Jul 2021 | A1 |
| 20210244940 | Liberatore et al. | Aug 2021 | A1 |
| 20210244950 | Ironi et al. | Aug 2021 | A1 |
| 20210252278 | Hamner et al. | Aug 2021 | A1 |
| 20210260379 | Charlesworth et al. | Aug 2021 | A1 |
| 20210266011 | Chen et al. | Aug 2021 | A1 |
| 20210283400 | Hamner et al. | Sep 2021 | A1 |
| 20210289814 | Roubos-van den Hil et al. | Sep 2021 | A1 |
| 20210299445 | Rajguru et al. | Sep 2021 | A1 |
| 20210308460 | Wong et al. | Oct 2021 | A1 |
| 20210330547 | Moaddeb et al. | Oct 2021 | A1 |
| 20210330974 | Wong et al. | Oct 2021 | A1 |
| 20210353181 | Roh | Nov 2021 | A1 |
| 20210379374 | Hamner et al. | Dec 2021 | A1 |
| 20210379379 | Campean et al. | Dec 2021 | A1 |
| 20210402172 | Ross et al. | Dec 2021 | A1 |
| 20220001164 | Sharma et al. | Jan 2022 | A1 |
| 20220016413 | John et al. | Jan 2022 | A1 |
| 20220031245 | Bresler | Feb 2022 | A1 |
| 20220054820 | Turner | Feb 2022 | A1 |
| 20220054831 | McBride | Feb 2022 | A1 |
| 20220088373 | Burnett | Mar 2022 | A1 |
| 20220126095 | Rajguru et al. | Apr 2022 | A1 |
| 20220143402 | Oppenheim et al. | May 2022 | A1 |
| 20220212007 | Rajguru et al. | Jul 2022 | A1 |
| 20220218991 | Moaddeb et al. | Jul 2022 | A1 |
| 20220220276 | Ziebell et al. | Jul 2022 | A1 |
| 20220233860 | Hamner et al. | Jul 2022 | A1 |
| 20220266011 | Hamner et al. | Aug 2022 | A1 |
| 20220266012 | Hamner et al. | Aug 2022 | A1 |
| 20230009158 | Liberatore | Jan 2023 | A1 |
| 20230191126 | Kent et al. | Jun 2023 | A1 |
| 20230201584 | Rajguru et al. | Jun 2023 | A1 |
| 20240189594 | Hamner et al. | Jun 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 1135722 | Nov 1996 | CN |
| 1547483 | Nov 2004 | CN |
| 1826154 | Aug 2006 | CN |
| 101022849 | Aug 2007 | CN |
| 101115524 | Jan 2008 | CN |
| 101365373 | Feb 2009 | CN |
| 101687093 | Mar 2010 | CN |
| 101801453 | Aug 2010 | CN |
| 102089031 | Jun 2011 | CN |
| 102481394 | May 2012 | CN |
| 202724457 | Feb 2013 | CN |
| 103517732 | Jan 2014 | CN |
| 103889503 | Jun 2014 | CN |
| 104144729 | Nov 2014 | CN |
| 104168951 | Nov 2014 | CN |
| 104519960 | Apr 2015 | CN |
| 105457158 | Apr 2016 | CN |
| 105848710 | Aug 2016 | CN |
| 106413805 | Feb 2017 | CN |
| 106687161 | May 2017 | CN |
| 106794347 | May 2017 | CN |
| 107949421 | Apr 2018 | CN |
| 108697890 | Oct 2018 | CN |
| 102008042373 | Apr 2010 | DE |
| 102009004011 | Jul 2010 | DE |
| 0000759 | Feb 1979 | EP |
| 0725665 | Jan 1998 | EP |
| 1062988 | Dec 2000 | EP |
| 1558333 | May 2007 | EP |
| 1727591 | Apr 2009 | EP |
| 2383014 | Nov 2011 | EP |
| 2291115 | Sep 2013 | EP |
| 2801389 | Nov 2014 | EP |
| 3020448 | May 2016 | EP |
| 2029222 | Mar 2017 | EP |
| 2780073 | Sep 2017 | EP |
| 1951365 | Oct 2017 | EP |
| 3154627 | Apr 2018 | EP |
| 2827771 | May 2018 | EP |
| 3184143 | Jul 2018 | EP |
| 3075412 | Dec 2018 | EP |
| 3349712 | Jul 2019 | EP |
| 3503960 | Mar 2020 | EP |
| 3352846 | Jul 2020 | EP |
| 3493874 | Aug 2020 | EP |
| 3409200 | Sep 2020 | EP |
| 3427793 | Nov 2020 | EP |
| 3758595 | Jan 2021 | EP |
| 3641876 | Apr 2021 | EP |
| 3679979 | Jun 2021 | EP |
| 3402404 | Jul 2021 | EP |
| 3562541 | Jul 2021 | EP |
| 3675795 | Aug 2021 | EP |
| 3100765 | Jan 2022 | EP |
| 4108292 | Dec 2022 | EP |
| 2222819 | Mar 2006 | ES |
| 2272137 | Jun 2008 | ES |
| 2496449 | May 2013 | GB |
| 2010-527256 | Jan 1900 | JP |
| 2002200178 | Jul 2002 | JP |
| 2003-501207 | Jan 2003 | JP |
| 2003-533299 | Nov 2003 | JP |
| 2004-512104 | Apr 2004 | JP |
| 2006-503658 | Feb 2006 | JP |
| 2008018235 | Jan 2008 | JP |
| 200934328 | Feb 2009 | JP |
| 2009-512516 | Mar 2009 | JP |
| 2009529352 | Aug 2009 | JP |
| 2010506618 | Mar 2010 | JP |
| 2010512926 | Apr 2010 | JP |
| 2010-246745 | Nov 2010 | JP |
| 2012005596 | Jan 2012 | JP |
| 2012055650 | Mar 2012 | JP |
| 2012-217565 | Nov 2012 | JP |
| 2013017609 | Jan 2013 | JP |
| 2013094305 | May 2013 | JP |
| 54-39921 | Mar 2014 | JP |
| 2015-514460 | May 2015 | JP |
| 2016-511651 | Apr 2016 | JP |
| 2018-038597 | Mar 2018 | JP |
| 20130104446 | Sep 2013 | KR |
| WO 198701024 | Feb 1987 | WO |
| WO1994000187 | Jan 1994 | WO |
| WO1994017855 | Aug 1994 | WO |
| WO1996032909 | Oct 1996 | WO |
| WO1998043700 | Oct 1998 | WO |
| WO1999019019 | Apr 1999 | WO |
| WO2000015293 | Mar 2000 | WO |
| WO 2001087411 | Nov 2001 | WO |
| WO2002017987 | Mar 2002 | WO |
| WO 2002034327 | May 2002 | WO |
| WO 2004037344 | May 2004 | WO |
| WO 2004108209 | Dec 2004 | WO |
| WO 2005007029 | May 2005 | WO |
| WO2005122894 | Dec 2005 | WO |
| WO 2006021820 | Mar 2006 | WO |
| WO 2006092007 | Sep 2006 | WO |
| WO 2006102724 | Oct 2006 | WO |
| WO 2007092290 | Aug 2007 | WO |
| WO2007112092 | Oct 2007 | WO |
| WO 2008045598 | Apr 2008 | WO |
| WO 2008062395 | May 2008 | WO |
| WO 2008106174 | Sep 2008 | WO |
| WO2009153730 | Dec 2009 | WO |
| WO 2010014260 | Feb 2010 | WO |
| WO2010111321 | Sep 2010 | WO |
| WO2010141155 | Dec 2010 | WO |
| WO2011119224 | Sep 2011 | WO |
| WO2011144883 | Nov 2011 | WO |
| WO 2011149656 | Dec 2011 | WO |
| WO2012040243 | Mar 2012 | WO |
| WO2013071307 | May 2013 | WO |
| WO2013074809 | May 2013 | WO |
| WO 2013173727 | Nov 2013 | WO |
| WO2014043757 | Mar 2014 | WO |
| WO2014053041 | Apr 2014 | WO |
| WO 2014070999 | May 2014 | WO |
| WO 2014089549 | Jun 2014 | WO |
| WO 2014093964 | Jun 2014 | WO |
| WO2014113813 | Jul 2014 | WO |
| WO2014146082 | Sep 2014 | WO |
| WO2014151431 | Sep 2014 | WO |
| WO2014153201 | Sep 2014 | WO |
| WO2014207512 | Dec 2014 | WO |
| WO2015033152 | Mar 2015 | WO |
| WO2015039206 | Mar 2015 | WO |
| WO2015039244 | Mar 2015 | WO |
| WO2015042365 | Mar 2015 | WO |
| WO2015079319 | Jun 2015 | WO |
| WO2015095880 | Jun 2015 | WO |
| WO2015128090 | Sep 2015 | WO |
| WO 2015138981 | Sep 2015 | WO |
| WO2015164706 | Oct 2015 | WO |
| WO2015187712 | Dec 2015 | WO |
| WO2016007093 | Jan 2016 | WO |
| WO2016019250 | Feb 2016 | WO |
| WO2016094728 | Jun 2016 | WO |
| WO2016102958 | Jun 2016 | WO |
| WO2016110804 | Jul 2016 | WO |
| WO2016128985 | Aug 2016 | WO |
| WO2016149751 | Sep 2016 | WO |
| WO2016166281 | Oct 2016 | WO |
| WO 2016176668 | Nov 2016 | WO |
| WO2016179407 | Nov 2016 | WO |
| WO2016189422 | Dec 2016 | WO |
| WO2016195587 | Dec 2016 | WO |
| WO2016201366 | Dec 2016 | WO |
| WO2017004021 | Jan 2017 | WO |
| WO2017010930 | Jan 2017 | WO |
| WO2017023864 | Feb 2017 | WO |
| WO 2017044904 | Mar 2017 | WO |
| WO2017053847 | Mar 2017 | WO |
| WO2017062994 | Apr 2017 | WO |
| WO2017086798 | May 2017 | WO |
| WO2017088573 | Jun 2017 | WO |
| WO2017132067 | Aug 2017 | WO |
| WO2017199026 | Nov 2017 | WO |
| WO2017208167 | Dec 2017 | WO |
| WO2017209673 | Dec 2017 | WO |
| WO2017210729 | Dec 2017 | WO |
| WO2017221037 | Dec 2017 | WO |
| WO2018009680 | Jan 2018 | WO |
| WO2018028170 | Feb 2018 | WO |
| WO2018028220 | Feb 2018 | WO |
| WO2018028221 | Feb 2018 | WO |
| WO2018039458 | Mar 2018 | WO |
| WO2018093765 | May 2018 | WO |
| WO 2018106839 | Jun 2018 | WO |
| WO2018112164 | Jun 2018 | WO |
| WO 2018119220 | Jun 2018 | WO |
| WO2018187241 | Oct 2018 | WO |
| WO2019005774 | Jan 2019 | WO |
| WO2019014250 | Jan 2019 | WO |
| WO2019028000 | Feb 2019 | WO |
| WO 2019046180 | Mar 2019 | WO |
| WO 2019082180 | Jun 2019 | WO |
| WO 2019143790 | Jul 2019 | WO |
| WO 2019169240 | Sep 2019 | WO |
| WO 2019202489 | Oct 2019 | WO |
| WO 2019213433 | Nov 2019 | WO |
| WO 2020006048 | Jan 2020 | WO |
| WO 2020068830 | Apr 2020 | WO |
| WO 2020069219 | Apr 2020 | WO |
| WO2020086726 | Apr 2020 | WO |
| WO 2020131857 | Jun 2020 | WO |
| WO 2020185601 | Sep 2020 | WO |
| WO 2021005584 | Jan 2021 | WO |
| WO 2021055716 | Mar 2021 | WO |
| WO 2021062345 | Apr 2021 | WO |
| WO 2021127422 | Jun 2021 | WO |
| WO 2021228128 | Nov 2021 | WO |
| WO 2021236815 | Nov 2021 | WO |
| WO 2021252292 | Dec 2021 | WO |
| WO 2022221858 | Oct 2022 | WO |
| WO 2023283568 | Jan 2023 | WO |
| WO 2023014499 | Feb 2023 | WO |
| WO 2023015158 | Feb 2023 | WO |
| WO 2023015159 | Mar 2023 | WO |
| Entry |
|---|
| U.S. Appl. No. 16/071,056, filed Jul. 18, 2018, Wong et al. |
| U.S. Appl. No. 16/327,780, filed Feb. 22, 2019, Hamner et al. |
| U.S. Appl. No. 16/833,388, filed Mar. 27, 2020, Hamner et al. |
| U.S. Appl. No. 16/780,758, filed Feb. 3, 20202, Wong et al. |
| Apartis; Clinical neurophysiology in movement disorders. Handb Clin Neurol; 111; Pediatric Neurology Pt. 1; pp. 87-92;Apr. 2013. |
| Barbaud et al.; Improvement in essential tremor after pure sensory stroke due to thalamic infarction; European neurology; 46; pp. 57-59; Jul. 2001. |
| Barrios et al.: BCI algorithms for tremor identification, characterization and tracking; Seventh Framework Programme, EU; Contract No. FP7-ICT-2007-224051 (v3.0); 57 pgs.; Jul. 10, 2011. |
| Bartley et al.; Neuromodulation for overactive bladder; Nature Reviews Urology; 10; pp. 513-521; Sep. 2013. |
| Benabid et al.; A putative generalized model of the effects and mechanism of action of high frequency electrical stimulation of the central nervous system; Acta Neural Belg; 105(3); pp. 149-157; Sep. 2005. |
| Bergquist et al.: Motor unit recruitment when neuromuscular electrical stimulation is applied over a nerve trunk compared with a muscle belly: quadriceps femoris, Journal of Applied Physiology; vol. 113, No. 1, pp. 78-89; Jul. 2012. |
| Bergquist et al.; Motor unit recruitment when neuromuscular electrical stimulation is applied over a nerve trunk compared with a muscle belly: triceps surae, Journal of Applied Physiology; vol. 110, No. 3, pp. 627-637; Mar. 2011. |
| Bijelic et al.: E Actitrode®: The New Selective Stimulation Interface for Functional Movements in Hemiplegic Patients; Serbian Journal of Electrical Engineering; 1(3); pp. 21-28; Nov. 2004. |
| Birdno et al.; Pulse-to-pulse changes in the frequency of deep brain stimulation affect tremor and modeled neuronal activity.; Journal of Neurophysiology; 98; pp. 1675-1684; Jul. 2007. |
| Birdno et al.; Response of human thalamic neurons to high-frequency stimulation.; PloS One; 9(5); 10 pgs.; May 2014. |
| Birgersson et al.; Non-invasive bioimpedance of intact skin: mathematical modeling and experiments; Physiological Measurement; 32(1); pp. 1-18; Jan. 2011. |
| Bohling et al.; Comparison of the stratum corneum thickness measured in vivo with confocal Raman spectroscopy and confocal reflectance microscopy; Skin research and Technology; 20(1); pp. 50-47; Feb. 2014. |
| Bonaz, B., V. Sinniger, and S. Pellissier. “Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease.” Journal of internal medicine 282.1 (2017): 46-63. |
| Bowman et al.; Effects of waveform parameters on comfort during transcutaneous neuromuscular electrical stimulation; Annals of Biomedical Engineering; 13(1); pp. 59-74; Jan. 1985. |
| Bratton et al.; Neural regulation of inflammation: no neural connection from the vagus to splenic sympathetic neurons; Exp Physiol 97.11 (2012); pp. 1180-1185. |
| Brittain et al.; Tremor suppression by rhythmic transcranial current stimulation; Current Biology; 23; pp. 436-440; Mar. 2013. |
| Britton et al.; Modulation of postural tremors at the wrist by supramaximal electrical median nerve shocks in ET, PD, and normal subjects mimicking tremor; J Neurology, Neurosurgery, and Psychiatry; 56(10); pp. 1085-1089; Oct. 1993. |
| Buschbacher et al.; Manual of nerve conduction series; 2nd edition; Demos Medical Publishing, LLC; 2006 (part 1, Title to p. #142). |
| Buschbacher et al.; Manual of nerve conduction series; 2nd edition; Demos Medical Publishing, LLC; 2006 (part 2, p. #143 to #299). |
| Cagnan et al.; Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation; Brain; 136(10); pp. 3062-3075; Oct. 2013. |
| Campero et al.; Peripheral projections of sensory fasicles in the human superificial radial nerve; Brain; 128(Pt 4); pp. 892-895; Apr. 2005. |
| Chen et al.; A web-based system for home monitoring of patients with Parkinson's disease using wearable sensors; IEEE Trans on Bio-Medical Engineering; 58(3); pp. 831-836; Mar. 2011. |
| Choi, Jong Bo, et al. “Analysis of heart rate variability in female patients with overactive bladder.” Urology 65.6 (2005): 1109-1112. |
| Clair et al.; Postactivation depression and recovery of reflex transmission during repetitive electrical stimulation of the human tibial nerve, Journal of Neurophysiology; vol. 106, No. 1; pp. 184-192; Jul. 2011. |
| Clar et al.; Skin impedance and moisturization; J. Soc. Cosmet. Chem.; 26; pp. 337-353; 1975; presented at IFSCC Vilith Int'l Congresson Cosmetics Quality and Safety in London on Aug. 26-30, 1974. |
| Constandinou et al.; A Partial-Current-Steering Biphasic Stimulation Driver for Vestibular Prostheses; IEEE Trans on Biomedical Circuits and Systems; 2(2); pp. 106-113; Jun. 2008. |
| Daneault et al.; Using a smart phone as a standalone platform for detection and monitoring of pathological tremors; Frontiers in Human Neuroscience; vol. 6, article 357; 12 pgs.; Jan. 2012. |
| Deuschl et at; Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee., Movement Disorders, vol. 13 Suppl 3, pp. 2-23; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 1998. |
| Di Giovangiulio et al.; The Neuromodulation of the intestinal immune system and its relevance in inflammatory bowel disease; Fronteir's in Immunology; vol. 6; Article 590; Nov. 2015. |
| Dideriksen et al.; EMG-based characterization of pathological tremor using the iterated Hilbert transform; IEEE transactions on Bio-medical Engineering; 58(10); pp. 2911-2921; Oct. 2011. |
| Dosen et al.: Tremor suppression using electromyography and surface sensory electrical stimulation; Converging Clinical and Engineering Research on Neurorehabilitation; vol. 1 (Siosystems & Biorobotics Series); pp. 539-543; Feb. 2013. |
| Doucet et al.; Neuromuscular electrical stimulation for skeletal muscle function; The Yale Journal of Biology and Medicine; 85(2); pp. 201-215; Jun. 2012. |
| Extended European Search Report dated Jul. 29, 2019 in European Application No. 17744724.0 in 6 pages. |
| Fuentes et al.; Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach, Eur J Neurosci, vol. 32, pp. 1100-1108; Oct. 2010 (author manuscript; 19 pgs.). |
| Fuentes et al.; Spinal cord stimulation restores locomotion in animal models of Parkinson's disease; Science; 323; pp. 1578-1582; Mar. 2009. |
| Gallego et al.; A neuroprosthesis for tremor management through the control of muscle co-contraction; Journal of Neuroengineering and Rehabilitation; vol. 10; 36; (13 pgs); Apr. 2013. |
| Gallego et al; A soft wearable robot for tremor assessment and suppression; 2011 IEEE International Conference on Robotics and Automation; Shanghai International Conference Center; pp. 2249-2254; May 9-13, 2011. |
| Gallego et al.; Real-time estimation of pathological tremor parameters from gyroscope data.; Sensors; 10(3); pp. 2129-2149; Mar. 2010. |
| Gao; Analysis of amplitude and frequency variations of essential and Parkinsonian tremors; Medical & Biological Engineering & Computing; 42(3); pp. 345-349; May 2004. |
| Garcia et al.; Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients; Pain; International Association for the Study of Pain; 2017. |
| Garcia-Rill, E., et al. “Arousal, motor control, and Parkinson's disease.” Translational neuroscience 6.1 pp. 198-207 (2015). |
| Giuffridda et al.; Clinically deployable Kinesia technology for automated tremor assessment.; Movement Disorders; 24(5); pp. 723-730; Apr. 2009. |
| Gracanin et al.; Optimal stimulus parameters for minimum pain in the chronic stimulatin of innervated muscle; Archives of Physical Medicine and Rehabilitation; 56(6); pp. 243-249; Jun. 1975. |
| Haeri et al.; Modeling the Parkinson's tremor and its treatments; Journal of Theorectical Biology; 236(3); pp. 311-322; Oct. 2005. |
| Halon EN et al.; Contribution of cutaneous and muscle afferent fibres to cortical SEPs following median and radial nerve stimulation in man; Electroenceph. Clin. Neurophysiol.; 71(5); pp. 331-335; Sep.-Oct. 1988. |
| Hao et al.; Effects of electrical stimulation of cutaneous afferents on corticospinal transmission of tremor signals in patients with Parkinson's disease; 6th International Conference on Neural Engineering; San Diego, CA; pp. 355-358; Nov. 2013. |
| Hauptmann et al.; External trial deep brain stimulation device for the application of desynchronizing stimulation techniques; Journal of Neural Engineering; 6; 12 pgs.; Oct. 2009. |
| Heller et al.; Automated setup of functional electrical stimulation for drop foot using a novel 64 channel prototype stimulator and electrode array: Results from a gait-lab based study; Medical Engineering & Physic; 35(1); pp. 74-81; Jan. 2013. |
| Henry Dreyfuss Associates; The Measure of Man and Woman: Human Factors in Design (Revised Edition); John Wiley & Sons, New York; pp. 10-11 and 22-25; Dec. 2001. |
| Hernan, Miguel, et al. “Alcohol Consumption and the Incidence of Parkinson's Disease.” May 15, 2003. Annals of Neurology. vol. 54. pp. 170-175. |
| Hua et al.; Posture-related oscillations in human cerebellar thalamus in essential tremor are enabled by voluntary motor circuits; J Neurophysiol; 93(1); pp. 117-127; Jan. 2005. |
| Huang, et al.; Theta burst stimulation report of the human motor cortex; Neuron, vol. 45, 201-206, Jan. 20, 2005. |
| Hubeaux, Katelyne, et al. “Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence.” The Journal of urology 178.6 (2007): 2483-2487. |
| Hubeaux, Katelyne, et al. “Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome.” Neurourology and urodynamics 30.8 (2011): 1467-1472. |
| Inoue, Masahiro, Katsuaki Suganuma, and Hiroshi Ishiguro. “Stretchable human interface using aconductive silicone elastomer containing silver fillers.” Consumer Electronics, 2009. ISCE'09. IEEE 13th International Symposium on. IEEE, 2009. |
| Jacks et al.; Instability in human forearm movements studied with feed-back-controlled electrical stimulation of muscles; Journal of Physiology; 402; pp. 443-461; Aug. 1988. |
| Jobges et al.; Vibratory proprioceptive stimulation affects Parkinsonian tremor; Parkinsonism & Related Disorders; 8(3); pp. 171-176; Jan. 2002. |
| Joundi et al.; Rapid tremor frequency assessment with the iPhone accelerometer.; Parkinsonism & Related Disorders; 17(4); pp. 288-290; May 2011. |
| Kim et al.: Adaptive control of movement for neuromuscular stimulation-assisted therapy in a rodent model; IEEE Trans on Biomedical Engineering,; 56(2); pp. 452-461; Feb. 2009. |
| Krauss et al.; Chronic spinal cord stimulation in medically intractable orthostatic tremor; J Neurol Neurosurg Psychiatry; 77(9); pp. 1013-1016; Sep. 2006. |
| Kuhn et al.; Array electrode design for transcutaneous electrical stimulation a simulation study; Medical Engineering & Physics; 31 (8); pp. 945-951; Oct. 2009. |
| Kuhn et al.; The Influence of Electrode Size on Selectivity and Comfort in Transcutaneous Electrical Stimulation of the Forearm; Neural Systems and Rehabilitation Engineering, IEEE Transactions on; 18(3); pp. 255-262; Jun. 2010. |
| Kunz, Patrik, et al. “5 kHz transcranial alternating current stimulation: lack of cortical excitability changes when grouped in a theta burst pattern.” Frontiers in Human Neuroscience 10 (2016): 683. |
| Lagerquist et al.: Influence of stimulus pulse width on M-waves, H-reflexes, and torque during tetanic low-intensity neuromuscular stimulation, Muscle & Nerve, 42(6), pp. 886-893; Dec. 2010. |
| Laroy et al.; The sensory innervation pattern of the fingers; J. Neurol.; 245 (5); pp. 294-298; May 1998. |
| Lee et al.; Resetting of tremor by mechanical perturbations: A comparison of essential tremor and parkinsonian tremor; Annals of Nuerology; 10(6); pp. 523-531; Dec. 1981. |
| Legon et al.; Pulsed ultrasound differentially stimulates somatosensory circuits in humans as indicated by EEG and fMRI; PLoS ONE; 7(12); e51177; 14 pgs.; Dec. 2012. |
| Liao, Wen-Chien, et al. “A noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder.” International Journal of Gynecology & Obstetrics 110.1 (2010): 12-17. |
| Lourenco et al.; Effects produced in human arm and forearm motoneurones after electrical stimulation of ulnar and median nerves at wrist level; Experimental Brain Research; 178(2); pp. 267-284; Apr. 2007. |
| Malek et al.; The utility of electromyography and mechanomyography for assessing neuromuscular function: a noninvasive approach; Phys Med Rehabil in N Am; 23(1); pp. 23-32; Feb. 2012. |
| Mamorita et al.; Development of a system for measurement and analysis of tremor using a three-axis accelerometer; Methods Inf Med; 48(6); pp. 589-594; epub Nov. 2009. |
| Maneski et al.; Electrical Stimulation for suppression of pathological tremor; Med Biol Eng Comput; 49(10); pp. 1187-1193; Oct. 2011. |
| Marsden et al.; Coherence between cerebellar thalamus, cortex and muscle in man; Brain; 123; pp. 1459-1470; Jul. 2000. |
| Marshall, Ryan, et al. “Bioelectrical stimulation for the reduction of inflammation in inflammatory bowel disease.” Clinical Medicine Insights: Gastroenterology 8 (2015): CGast-S31779. |
| McAuley et al.; Physiological and pathological tremors and rhythmic central motor control; Brain; 123(Pt 8); pp. 1545-1567; Aug. 2000. |
| McIntyre et al.; Finite element analysis of current-density and electric field generated by metal microelectrodes; Annals of Biomedical Engineering; 29(3); pp. 227-235; Mar. 2001. |
| Meekins et al.; American Association of Neuromuscular & Electrodiagnostic Medicine evidenced-based review: use of surface electromyography in the diagnosis and study of neuromuscular disorders; Muscle Nerve 38(4); pp. 1219-1224; Oct. 2008. |
| Mehnert, Ulrich, et al. “Heart rate variability: an objective measure of autonomic activity and bladder sensations during urodynamics.” Neurourology and urodynamics 28.4 (2009): 313-319. |
| Miguel et al.; Alcohol consumption and the incidence of Parkinson's disease; Ann. Neurol.; 54(2); pp. 170-175; May 15, 2003. |
| Miller et al.; Multiplexed microneedle-based biosensor array for characterization of metabolic acidosis; Talanta; 88; pp. 739-742; Jan. 2012 (author manuscript; 13 pgs.). |
| Miller et al.; Neurostimulation in the treatment of primary headaches; Pract Neurol; Apr. 11, 2016;16:pp. 362-375. |
| Milne et al.; Habituation to repeated in painful and non-painful cutaneous stimuli: A quantitative psychophysical study; Experimental Brain Research; 87(2); pp. 438-444; Nov. 1991. |
| Mones et al.; The response of the tremor of patients with Parkinsonism to peripheral nerve stimulation; J Neurology, Neurosurgery, and Psychiatry; 32(6); pp. 512-518; Dec. 1969. |
| Mommaerts et al.; Excitation and nerve conduction; in Comprehensive Human Physiology; Springer Berlin Heidelberg; Chap. 13; pp. 283-294; Mar. 1996. |
| Morgante et al.: How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus?; Results of a Questionnaire, Partkinsonism Relat Disord; 13; pp. 528-531; Dec. 2007. |
| Munhoz et al; Acute effect of transcutaneous electrical nerve stimulation on tremor; Movement Disorders; 18(2); pp. 191-194; Feb. 2003. |
| Nardone et al.; Influences of transcutaneous electrical stimulation of cutaneous and mixed nerves on subcortical somatosensory evoked potentials; Electroenceph. Clin. Neurophysiol.; 74(1); pp. 24-35; Jan.-Feb. 1989. |
| Nonis et al.; Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: An electrophysiological study in healthy volunteers; Cephalalgia; pp. 1285-1293; vol. 37(13); Mar. 28, 2017. |
| PCT Search Report and Written Opinion in PCT Application No. PCT/US2017/014431 mailed Sep. 7, 2017 in 19 pages. |
| PCT Search Report and Written Opinion in PCT Application No. PCT/US2018/025752 mailed Jun. 21, 2018 in 21 pages. |
| Perez et al.; Patterned Sensory Stimulation Induces Plasticity in Reciprocal la Inhibition in Humans; The Journal of Neuroscience; 23(6); pp. 2014-2018; Mar. 2003. |
| Perlmutter et al.; Deep brain stimulation; Ann Rev Neurosci; 29; pp. 229-257; Jul. 2006. |
| Popović-Bijelić, Ana, et al. Multi-field surface electrode for selectiveorgans 29.6 (2005): 448-452. |
| Prochazka et al.; Attenuation of pathological tremors by functional electrical stimulation I: Method; Annals of Biomedical Engineering; 20(2); pp. 205-224; Mar. 1992. |
| Pulliam et al.; Continuous in-home monitoring of essential tremor; Parkinsonism Relat Disord; 20(1); pp. 37-40; Jan. 2014. |
| Quattrini et al.; Understanding the impact of painful diabetic neuropathy; Diabetes/Metabolism Research and Reviews; 19, Suppl. 1; pp. S2-S8; Jan.-Feb. 2003. |
| Rocon et al.; Design and validation of a rehabilitation robotic exoskeleton for tremor assessment and suppression; IEEE Trans Neural Sys and Rehab Eng.; 15(3); pp. 367-378; Sep. 2007. |
| Silverstone et al.; Non-Invasive Neurostimulation in the Control of Familial Essential Tremor Using the Synaptic Neuromodulator; Conference Proceedings, International Functional Electrical Stimulation Society (IFES); Ed. Paul Meadows; 3 pgs.; May 1999. |
| Singer et al.; The effect of EMG triggered electrical stimulation plus task practice on arm function in chronic stroke patients with moderate-severe arm deficits; Restor Neurol Neurosci; 31(6); pp. 681-691; Oct. 2013. |
| Straube et al.; Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial; The Journal of Headache and Pain (2015) 16:63. |
| Takanashi et al.; A functional MRI study of somatotopic representation of somatosensory stimulation in the cerebellum; Neuroradiology; 45(3); pp. 149-152; Mar. 2003. |
| Tass et al.; Coordinated reset has sustained aftereffects in Parkinsonian monkeys; Ann Neurol; 72(5); pp. 816-820; Nov. 2012. |
| Tass et al.; Counteracting tinnitus by acoustic coordinated reset neuromodulation; Restorative neurology and Neuroscience; 30(2); pp. 137-159; Apr. 2012. |
| Tass; A Model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations; Bioi Cybern; 89(2); pp. 81-88; Aug. 2003. |
| Thomas et al.; A review of posterior tibial nerve stimulation for faecal incontinence; Colorectal Disease; 2012 the Association of Coloproctology of Great Britain and Ireland. 15, pp. 519-526; Jun. 25, 2012. |
| Toloso et al.; Essential tremor: treatment with propranolol; Neurology; 25(11); pp. 1041; Nov. 1975. |
| Tracey; The inflammatory reflex; Nature; vol. 420; pp. 853-859; Dec. 19-26, 2002. |
| Treager; Interpretation of skin impedance measurements; Nature; 205; pp. 600-601; Feb. 1965. |
| Valente; Novel methods and circuits for field shaping in deep brain stimulation; Doctoral thesis, UCL (University College London); 222 pgs.; 2011. |
| Vitton et al.; Transcutaneous posterior tibial nerve stimulation for fecalIncontinence in inflammatorybowel disease patients: a therapeutic option?; Inflamm Bowel Dis; vol. 15, No. 3, Mar. 2009; pp. 402-405. |
| Von Lewinski et al.; Efficacy of EMG-triggered electrical arm stimulation in chronic hemiparetic stroke patients; Restor Neurol Neurosci; 27(3); pp. 189-197; Jun. 2009. |
| Wardman et al.; Subcortical, and cerebellar activation evoked by selective stimulation of muscle and cataneous afferents: an fMRI study; Physiol. Rep.; 2(4); pp. 1-16; Apr. 2014. |
| Wiestler et al.; Integration of sensory and motor representations of single fingers in the human; J. Neurophysiol.; 105(6); pp. 3042-3053; Jun. 2011. |
| Woldag et al.; Evidence-based physiotherapeutic concepts for improving arm and hand function in stroke patients R A review; J Neurol; 249(5); pp. 518-528; May 2002. |
| Woolf et al.; Peripheral nerve injury triggers central sprouting of myelinated afferents; Nature; 355(6355); pp. 75-78; Jan. 1992. |
| Yarnitsky et al.; Nonpainful remote electrical stimulation alleviates episodic migraine pain; Neurology 88; pp. 1250-1255; Mar. 28, 2017. |
| Yeh, Kuei-Lin, Po-Yu Fong, and Ying-Zu Huang. “Intensity sensitive modulation effect of theta burst form of median nerve stimulation on the monosynaptic spinal reflex.” Neural plasticity 2015 (2015) in 8 pages. |
| Yilmaz, Ozlem O., et al. “Efficacy of EMG-biofeedback in knee osteoarthritis.” Rheumatology international 30.7 (2010): 887-892. |
| Zhang et al.; Neural oscillator based control for pathological tremor suppression via functional electrical stimulation; Control Engineering Practice; 19(1); pp. 74-88; Jan. 2011. |
| Zorba et al.; Overactive bladder and the pons; Rize University, Medical Faculty, Department of Urology; 123-124; Undated. |
| Zwarts et al.; Multichannel surface EMG: basic aspects and clinical utility; Muscle Nerve; 28(1); pp. 1-17; Jul. 2003. |
| U.S. Appl. No. 16/792,100, filed Feb. 14, 2020, Hamner et al. |
| Amarenco et al. “Urondynamic Effect of Acute Transcutaneous Posterior Tibial Nerve Stimulation in Overactive Bladder” Journal of Urology vol. 169, 2210-2215 (Jun. 2003). |
| Barath et al., 2020, Brain metabolic changes with longitudinal transcutaneous afferent patterned stimulation in essential tremor subjects, Tremor and Other Hyperkinetic Movements, 10(1):52, pp. 1-10. |
| Brillman et al., 2022, Real-world evidence of transcutaneous afferent patterned stimulation for essential tremor, Tremor and Other Hyperkinetic Movements, 12(1):27, pp. 1-11. |
| Ferreira et al., 2019, MDS evidence-based review of treatments for essential tremor, Movement Disorders, 34(7):950-958. |
| Fiorentino et al., 2011, Self calibrating wearable active running asymmetry measurement and correction, Journal of Control Engineering and Applied Informatics, 13(2):3-8. |
| Fred E. Govier, et al., “Percutaneous Afferent Neuromodulation for the Refractory Overactive Bladder: Results of a Multicenter Study,” 165 J. Urology 1193-1198 (Apr. 2001). |
| Gupta et al., 2021, Exploring essential tremor: results from a large online survey, Clinical Parkinsonism & Related Disorders, 5:100101, 4 pp. |
| H.C. Klingler, et al., “Use of Peripheral Neuromodulation of the S3 Region for Treatment of Detrusor Overactivity: A Urodynamicbased Study,” Urology 56:766-771, 2000. |
| Haubenberger et al., 2018, Essential Tremor, the New England Journal of Medicine, 378:1802-1810 and Supplementary Appendix. |
| Hellwig et al., Feb. 17, 2001, Tremor-correlated cortical activity in essential tremor, the Lancet, 357:519-523. |
| Hernandez-Martin et al., 2021, High-fidelity transmission of high-frequency burst stimuli from peripheral nerve to thalamic nuclei in children with dystonia, Scientific Reports, 11:8498, 9 pp. |
| Isaacson et al., 2020, Prospective home-use study on non-invasive neuromodulation therapy for essential tremor, Tremor and Other Hyperkinetic Movements, 10(1):29, pp. 1-16. |
| Krishnamoorthy et al., 2008, Gait Training After Stroke: A Pilot Study Combining a Gravity-Balanced Orthosis, Functional Electrical Stimulation, and Visual Feedback, Journal of Neurologic Physical Therapy, 32(4):192-202. |
| Lin et al., 2018, Noninvasive neuromodulation inessential tremor demonstrates relief in a sham-controlled pilot trial, Movement Disorders, 33(7):1182-1183. |
| Llinas et al., Dec. 21, 1999, Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography, PNAS, 96(26):15222-15227. |
| Lyons et al., 2021, Essential tremor in adult patients, International Essential Tremor Foundation, 16 pp. |
| Michael R. Van Balken, et al., “Posterior Tibial Nerve Stimulation as Neuromodulative Treatment of Lower Urinary Track Dysfunction,” 166 J. Urology 914-918 (Sep. 2001). |
| Pahwa et al., 2018, An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor, Neuromodulation, 22:537-545. |
| Peng et al., 2015, Flexible dry electrode based on carbon nanotube/polymer hybrid micropillars for biopotential recording, Sensor and Actuatora A: Physical, 235:48-65. |
| Perez-Reyes, Jan. 2003, Molecular physiology of low-voltage-activated T-type calcium channels, Physiol. Rev. 83:117-161. |
| Popovi Maneski et al.; Electrical stimulation for the suppression of pathological tremor; Medical & Biological Engineering & Computing; 49(10); pp. 1187-1193; Oct. 2011. |
| Sigrist et al., 2012. Augmented visual, auditory, haptic, and multimodal feedback in motor learning: A review. Psychonomic Bulletin & Review, 20(1):21-53. |
| Solomonow et al., 1998, Studies toward spasticity suppression with high frequency electrical stimulation, Orthopedics, 7(8):1284-1288. |
| Wallerberger, Apr. 4, 2019, Efficient Estimation of Autocorrelation Spectra, ArXiv.org, https://arxiv.org/abs/1810.05079. |
| Petition for Inter Partes Review of U.S. Pat. No. 9,387,338 (IPR2023-00511) dated Jan. 23, 2023. |
| Petition for Inter Partes Review of U.S. Pat. No. 9,757,584 (IPR2023-00508) dated Jan. 23, 2023. |
| Declaration of John Laughlin in Support of Petition for Inter Partes Review of U.S. Pat. No. 9,387,338 (IPR2023-00511—Ex. 1002) filed Jan. 23, 2023. |
| Declaration of John Laughlin in Support of Petition for Inter Partes Review of U.S. Pat. No. 9,757,584 (IPR2023-00508—Ex. 1002) filed Jan. 23, 2023. |
| Decision Granting Institution of Inter Partes Review of U.S. Pat. No. 9,387,338 (IPR2023-00511—Paper 7) dated Aug. 3, 2023. |
| Decision Granting Institution of Inter Partes Review of U.S. Pat. No. 9,757,584 (IPR2023-00508—Paper 7) dated Aug. 3, 2023. |
| Cala Trio Health Care Professional Guide (Jul. 2020). |
| Cala Trio Health Care Professional Guide (Nov. 2019). |
| Chang, M.D., Qwang-Yuen et al., Effect of Electroacupuncture and Transcutaneous Electrical Nerve Stimulation at Hegu (LI.4) Acupuncture Point on the Cutaneous Reflect, 27 Acupuncture & Electro-Therapeutics Res., Int. J. 191-202 (2002). |
| Javidan, et al, Attenuation of Pathological Tremors by Functional Electrical Stimulation II: Clinical Evaluation, 20 Annals of Biomedical Engineering 225 (1992). |
| Knutson et al., Neuromuscular Electrical Stimulation for Motor Restoration in Hemiplegia. Phys Med Rehabil Clin N A,. Nov. 2015; 26(4): 729-745. Published online Aug. 14, 2015. Doi: 10.1016/j.pmr.2015.06.002. |
| Final Written Decision of Inter Partes Review of Inter Partes Review of U.S. Pat. No. 9,757,584 (IPR2023-00508) dated Jul. 1, 2024. |
| Final Written Decision of Inter Partes Review of U.S. Pat. No. 9,387,338 (IPR2023-00511) dated Jul. 1, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20220266012 A1 | Aug 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62534074 | Jul 2017 | US | |
| 62481006 | Apr 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16500377 | US | |
| Child | 17663010 | US |
